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The microarray platform can be used in high-capacity, high-throughput screening tool for 
discovering the small molecular inhibitor for the protein-protein interaction. Chapter 2, 
by using a small molecule microarray as a high-throughput screening platform, we have 
successfully discovered two potent inhibitors D02 and D17 of cathepsin L which were 
converted strategically into the corresponding two-photon small molecule imaging probes 
(ZK-1 and ZK-2). In Chapter 3, a fragment-based small molecule library for BRCA1 
BRCT domain has been developed and we discovered the first cell-permeable small 
molecule that processes both in-vitro and in-cell activities. In Chapter 4, we have firstly 
identified the binding peptide motif of PARP1 BRCT domain from the microarray 
technology with two libraries, and further optimized a fluorescence polarization assay 
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Over the last decade, microarray screening technology has changed the life science 
research area. It is widely used in the area of mapping interaction networks to 
molecular fingerprinting and small molecular inhibitor discovery, and this technique 
has significantly impacted both basic and applied parts of research.
[1]
 Based on these, 
many creative ideas are generated by many biologists, chemists and engineers. Indeed, 
microarray technology was first introduced as miniaturized DNA assemblies on chips. 
However it did not take long before further pioneering efforts made it possible to 
immobilize small molecules and proteins in the grids for rapid analysis. And now it 
has also become feasible to examine a host of other biomolecules, including 
membrane proteins, carbohydrates, tissues, peptides and even live cells on arrays. It 
provides a tremendous opportunity for screening and large-scale analysis. And also it 
is remarkable that so many diverse applications have appeared from a single 
technology platform. It has the significant advantages in miniaturization, 
parallelization and automation. Indeed, the microarray offers a flat reaction surface 
that ameliorates the washing and incubation steps, while providing a significant 
higher sample density. This design concept makes it convenient to carry hundreds of 
thousands of assays quickly and reproducibly by reducing the amount of often 
precious reagents which require to performing highly informative experiments.  
Nowadays, small molecules, peptides and protein microarrays have witnessed huge 
growth in recent years.
[2]
 They show the high improvements made towards library 
creation and immobilization formats. And these developments, together with novel 
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advances, have set the foundation for these platforms to eventually take on more 
routine applications in diagnostics, especially in protein and enzyme inhibitor 
interaction discovery. The enzyme inhibitor is a molecule that binds to enzymes and 
decreases their activity. Because blocking an enzyme's activity can kill a pathogen or 
correct a metabolic imbalance, many drugs are enzyme inhibitors. The discovery and 
improvement of small drug molecules is an active area of research in biochemistry 
and pharmacology. A medicinal enzyme inhibitor is often judged by its specificity and 
its potency. The high specificity and potency ensure that a drug will have few side 







Figure 1.1 Overview of scheme for the protein-protein interaction inhibitors 
Besides, the small enzyme inhibitors are involved in the regulation of protein-protein 
interactions.
[3] 
Protein–protein interactions are central to most biological 
processes-from intercellular communication to programmed cell death, and therefore 
represent a large and important class of targets for human therapeutics. The current 
excitement surrounding therapeutic antibodies show the value of such targets. In  
2013, US $5–7 billion will be spent on antibody-based antagonists, the fastest 
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growing segment of the drug market. Targeting protein-protein interactions for small 
molecular inhibitor design means designing inhibitors that can specifically interact 
with target protein. Previously, scientists tried to use the natural product as the 
protein-protein interaction inhibitor. However, the natural products are not easy to 
synthesize and a lot chemicals to waste. Hence, one solution to solve this problem is 
that using easy synthesized small molecule inhibitors library by the microarray 
technique, to find out the best small molecular inhibitor for the protein-protein 
interaction. The more detailed discussion of previous and on-going research on this 
topic will be presented below. 
1.2 Protein-Protein interaction 
Protein–protein interactions occur when two or more proteins bind together, then to 
carry out their biological functions and features.
[4]
 Many of the most important 
molecular processes in the cell such as DNA replication, DNA damage and DNA 
repairs are carried out by large molecular machines that are built from a large number 
of protein components organized by their protein–protein interactions.[5] Protein 
interactions have been studied from the perspectives of biochemistry, molecular 
dynamics, molecular biology, chemical biology, signal transduction, post-translation 
modification and other metabolic and epigenetic networks. Indeed, protein–protein 





Figure 1.2 Protein-protein interaction view. 
Interactions between proteins are important for all of biological functions.
[6]
 For 
example, signals from the exterior of a cell are mediated to the inside of that cell by 
protein–protein interactions of the signaling transduction molecules. This process, 
called signal transduction, plays a fundamental role in many biological processes and 
in many diseases (e.g. cancers and leukaemia).
[7]
 Proteins might interact for a long 
time to form part of a protein complex, a protein may be carrying another protein (for 
example, from cytoplasm to nuclear), or a protein may interact briefly with another 
protein just to modify it and change it (for example, a protein kinase will transfer a 
phosphate to a substrate protein). This modification of proteins can itself change 
protein–protein interactions. For example, some proteins with BRCT domains only 
bind to other proteins when they are phosphorylated on the amino acid serine while 
bromodomains specifically recognise acetylated lysines. In conclusion, 
protein–protein interactions are crucially importance for virtually every process in the 
living cell. Information about these interactions increases our understanding of 





Figure 1.3 Protein domains in biology system. 
1.2.1 Protein domain 
A protein domain is a conserved part of a given protein sequence and structure that 
can evolve, function, and exist independently of the other part of the protein chain. 
Each domain forms a compact three-dimensional structure and often can be 
independently stable, folded and biological function. Many proteins consist of many 
structural domains.
[9]
 One domain could appear in a variety of different proteins.
[10]
 
Molecular evolution uses domains as building blocks and these may be recombined in 
different arrangements to create proteins with different functions. Domains change in 
length from about 90 amino acids up to 500 amino acids in length.
[11] 
1.2.1.1 Domains based on amino acid chain 
The primary structure (strain of amino acids) of a protein ultimately encodes its 
uniquely folded 3D conformation.
[12]
 The most important factor governing the folding 





Folding is driven by the burial of hydrophobic side chains into the interior of the 
molecule so to avoid contact with the aqueous environment from outside. Generally 
proteins have a core of hydrophobic residues surrounded by a shell of hydrophilic 
residues. Since the peptide bonds themselves are polar they are neutralised by 
hydrogen bonding with each other when in the hydrophobic environment. This gives 
rise to regions of the polypeptide that form regular 3D structural patterns called 
secondary structure. There are two main types of secondary structure: α-helices and 
β-sheets. For example, the β-hairpin motif consists of two adjacent antiparallel 
β-strands joined by a small loop. It is present in most antiparallel β structures both as 
an isolated ribbon and as part of more complex β-sheets. Another common secondary 
structure is the β-α-β motif, which is frequently used to connect two parallel β-strands. 
The central α-helix connects the C-termini of the first strand to the N-termini of the 
second strand, packing its side chains against the β-sheet and therefore shielding the 
hydrophobic residues of the β-strands from the surface.[14] Structural alignment is an 




Figure 1.4 3D structure of different protein domains 
1.2.1.2 Interaction Domains As Detectors of Posttranslational Modifications 
Protein modifications frequently complete binding sites for interaction domains. Such 
domains must achieve a balance between potency and specificity, because much of 
their binding energy comes from recognition of the modified residue. SH2 domains 
have a conserved pTyr-binding pocket, and they also recognize residues C-terminal to 
the pTyr in a fashion that differs from one SH2 domain to another.
[15]
 However, the 
ability of most SH2 domains to discriminate between different phosphorylated sites is 
by no means absolute, given the limited interaction surface available to provide 
selectivity while maintaining pTyr-dependent binding.
[16]
 Indeed, the SAP protein 
SH2 domain, which is mutated in human X-linked lymphoproliferative syndrome, has 
an extended phosphopeptide binding surface wing to its recognition of a threonine at 
the –2 position (relative to the Tyr), and as a consequence binds an unphosphorylated 
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peptide from the SLAM receptor with a dissociation constant of 500 nM. In this case, 
specificity is enhanced but recognition is not all dependent on phosphorylation of the 
binding target.
[17][18][19][20] 
1.2.2 BRCT domain  
BRCT (BRCA1 C-terminus) domains, initially identified in the breast and ovarian 
cancer susceptibility gene product BRCA1, are protein–protein interaction modules 
found in a wide area of prokaryotic and eukaryotic proteins ranging from one up to 
eight units.
[21][22][23][24][25] 
Germaine mutations that disrupt the BRCT domains of 
BRCA1 are associated with a significantly increased risk for breast and ovarian 
cancers. 
[26][27][28][29]
 The human genome contains at least 23 genes coding for proteins 
with BRCT domains and most are implicated in the DNA damage repaire. BRCT 
domains are originally found in all three superkingdoms: Archaea, Eubacteria, and 





Figure 1.5 BRCT domains in Bacteria and eukaryote 
1.2.2.1 BRCT domain structure 
The BRCT domain fold was first revealed in the crystal structure of the X-ray repair 
cross-complementing protein 1 (XRCC1) N-terminal BRCT domain.
[31][32][33][34][35]
 
The fold is comprised of a central 4-stranded β-sheet flanked by a single α-helix (α2) 
on one side and two α-helices (α1 and α3) on the opposite side. Comparison of all 
BRCT domain structures illustrate that deviations in structure and sequence are 
mainly localized to the connecting loops, whereas conserved residues are situated in 
the hydrophobic core and in residues involved in recognizing the phosphorylated 
amino acid in phosphopeptide targets.
[36][37][38]
 Interestingly, the domain architecture 
of BRCT domains is remarkably diverse. BRCT domains range from isolated 
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individual one domain to multiple tandem BRCT repeats, or even as fusions with 
other functional domains. Single BRCT domain represent a large class of BRCT 
domains that exist as single copies in proteins such as poly(ADP-ribose) polymerase 1 
(PARP1) and DNA Ligase III (Lig III).
[39]
 They can also be found in multiple but 
isolated copies, such as in XRCC1, where two distinct single BRCT domains are 
separated by 137 amino acids in sequence.
[40]
 In tandem BRCT repeats, multiple 
BRCT domains are separated by a variable linker region. The initial crystal structure 
of the tandem BRCT domains in BRCA1 shed light on the canonical BRCT-BRCT 
domain packing, which occurs through a hydrophobic interface consisting of the α2 





Figure 1.6 BRCT domain structure of the XRCC1 and BRCA1 
1.2.2.2 BRCT domain function in DNA damage 
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Functionally, BRCT containing proteins are involved in DNA damage and DNA repair, 
the DNA damage response and cell cycle regulation, most importantly by directing 
protein-protein interactions.
[46][47][48] 
In a number of cases, tandem BRCT repeats 
constitute a phosphopeptide binding domain with ligand specificity encoded in 
residues C-terminal to the critical phosphoserine. Phosphopeptide binding occurs in a 
groove that involves both the N- and C-terminal repeats and exhibits specificity for 
phospho-serine containing peptides.
[49]
  Yu et al. showed that these domains 
preferentially interact with a phosphopeptide library compared with the 
non-phosphorylated counterpart and that TopBP1 BRCT6 and hFCP1 BRCT 
specifically binds to cognate E2F1 and RNA polymerase II phosphopeptides, 
respectively.
[50]
 The conserved minimal phospho-peptide sequence bound by BRCT 
repeats consists of four residues (pS-X-X-X), in which the +3 residue dictates the 
majority of the binding specificity, especially for hydrophobic group.
[51]
 The +3 
residue sits in a cleft situated at the hydrophobic interface between the two BRCT 
domains, and conserved residues at the BRCT-BRCT interface determine the binding 
specificity for the +3 residue.
[52][53][54][55] 
BRCT domain protein 
 
Binding partners  Phosphopeptide ligands  





XRCC4  DNA Ligase IV 
 
TOPBP1  E2F1 
 
53BP1   p53 
 




MDC1/NFBD1  H2AX Ser-Ω-[EVDI]-Ω 
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Table 1.1 Different BRCT domain and binding partners 
1.3 Small molecule inhibitor for Protein-protein interaction 
The key role of protein-protein interactions in manifestation of numerous cell 
functions, their fine regulation and specificity attract attention to protein complexes as 
perspective drug targets. Recently the prevailing view was that protein–protein 
interactions are not perspective class since the protein-protein interfaces are too large 
and flat and binding energy is delocalized over all contact surfaces.
[56]
 So it appears 
that inhibition of protein– protein interaction by small (drug-like) molecules is quite 
difficult task. However, with rapidly increasing knowledge on nature of 
protein–protein interactions, development of methods for detection of new 
protein-protein interactions (such as yeast two-hybrid system, mass-spectrometry, 
etc.), the appearance of various of inhibitors of intermolecular interactions and wide 
effective employment the various antibodies as therapeutic agents, this field of 
medicinal chemistry is actively developed. Many cell processes depend on 
protein-protein interactions lacking enzymatic activity, activated or inhibited 
subsequent steps of metabolite or signal pathways. Indeed, the protein–protein 
interactions as drug targets can dramatically increase the number of acting points 
essential for the cell regulation and correction of the pathological processes. During 
the past decade it has become clear that compounds preventing or modifying 
protein–protein interactions of different classes of targets may have great therapeutic 
potential. Protein-protein interactions represent an important type of cellular targets 
for drug development. Besides the above mentioned these are also several types of 
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putative targets. They include protein/peptide receptor hormone antagonists,
[57][58]
 
signal transduction systems in the cell (SH2, BRCT and other domains),
[59][60][61]
 
protein– protein interactions in cell regulator pathways,[62][63][64][65] oligomeric 
enzymem,
[66][67]
 virus entry into the host, 
[68][69][70][71][72]
pathogenic protein aggregates 
(β-amyloid in Alzheimer disease, superoxide dismutase mutants in familial 
amyotrophic lateral sclerosis, a-synuclein, synphilin and parkin proteins forming 
Lewy bodies in Parkinson‟ disease and expanded glutamate repeats of huntingtin in 
Huntington's disease)etc.
[73][74][75][76][77][78] 
1.3.1 Starting Points of protein-protein inhibitor  
Only a few years ago the task of development of small, drug-like molecules inhibiting 
protein-protein interactions was consider as very difficult and challenge.
[79]
 At present 
time there are several successful examples of such inhibitors. The list of them can be 
found in recent reviews.
[80][81][82][83]
 This list includes peptides, peptidomimetics and 
small compounds. Although a variety of short peptides (4-15 amino acid residues) 
derived from one of subunit interfaces show inhibitory potency, their use as 
therapeutics is limited. The reasons for such “verdict” consist in their low oral 
bioavailability, quick degradation and poor pharmacokinetics.
[84]
 But such short 
peptide from contacted subunit with relatively high affinity can be “starting point” 
facilitating the development of small molecule protein-protein inhibitors. They can be 
used as a template for further optimization design of peptidomimetics: replacement of 
some amino acids residues, partial or total substitution of L-amino acids for their 





 These approaches can lead to peptidomimetics with high 
binding constants and selectivity.
[92][93]
 Discovery of inhibitors of SH2 domains 
represent good example of such approach. These domains recognize the short peptides 
containing phosphorylated tyrosine residues.
[94][95]
 The experimental and virtual 
screening and optimization by microarray methods lead to discovery different high 
affinity ligands (peptidomimetics and small molecules) with or without phosphate in 
their structures 
[96]
 The interfaces of interacting proteins often form by different 
secondary structures, alpha-helixes, beta-sheets, turns and unstructured elements.
[97]
  
So, the mimic of these secondary structures by small molecular compounds can be 
another “starting point”  for protein-protein inhibitors design. Several such structures 
of small compounds were discovered and some of them exhibited properties of 
protein-protein interaction inhibitors.
[98][99][100]
 In opposite case, when protein–protein 
interfaces do not have such continuous binding peptides, and interaction is attributed 
to the several amino acid residues (hot spots) localized at different parts of the contact 
interface discovery of small nonpeptide compounds is preferable or even the solely 
possible. As the binding site of protein-protein inhibitors is selected, the routine 
methods that such as docking, fragment-based drug design and de novo design are 
applicable.
[101][102][103]
 Thus, it seems that in general the small molecules are preferring 
compounds as protein-protein inhibitors. Moreover these compounds are covered by 
the diversity space of the commercial databases. So, small molecules able to inhibit 
the protein-protein interactions can be found in databases of commercially available 




1.3.2 Advantages and limitation of protein-protein interaction 
inhibitors 
What are the advantages and limitations of protein-protein inhibitors and their targets 
in comparison with inhibitors acting at active sites of enzymes?  
First of all, protein-protein inhibitors are a new class of potential drugs that can 
modulate cellular function by interacting with proteins lacking enzymatic activity. So 
regulation of protein-protein interaction by small compounds may be in some cases 
the main or special way for regulation of cellular responses. Signals from cell 
environment are detected by the surface receptors and are transduced into the cell by 
signaling cascades. These signaling cascades are commonly formed by protein-protein 
interaction networks that can be regarded as potential drug targets. Furthermore many 
enzymes are active as oligomers (mostly as homodimers). Frequently there active 
sites are formed by subunit-subunit contact.
[106]
 So their activity can be regulated not 
only by inhibitors interacting with active sites, but also by small compounds 
modifying their homodimer conditions. The intensive investigations by Chmielewski 
group have been directed for design HIV protease inhibitors preventing enzyme 
dimerization, which is active as homodimer and its active site is formed at the subunit 
interface.
[107][108]
 Systems of virus-cell entry and formation of protein/peptide 
aggregates (prions, β-amyloid etc) are the other examples of such 
targets.
[109][110][111][112][113] 
Secondly, protein-protein inhibitors are more “resistant” for spontaneous mutations at 
their binding site. Several investigations verified high conservatism of amino acid 
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residues of the contact interfaces in comparison with other parts of protein 
surfaces.
[114][115]
 The mutation on the interface of one subunit of the protein-protein 
complex often could require the complementary mutation in another subunit 
otherwise formation of functional protein complex may be changed and damaged. 
Such simultaneous double complementarity mutation in different subunits is rare 
event. Numerous data exist that a single mutation in one subunit of protein-protein 
interface can destroy or dramatically decrease of Kd of the protein-protein 
complex.
[116]
 This is particularly important for design of antibiotics drugs. One of the 
preferential mechanisms of antibiotic resistance is the mutation of amino acid residues 
in the active site of the antibiotic-targeted enzyme. Since the substrate and drugs can 
interact with the different groups at the active site, the mutation of an active site 
amino acid (but not catalytic residues) can lead to decreased affinity of the drug with 
little effect on substrate binding and enzyme activity. Resistance for inhibitors of 
active site can appear very quickly. At the end of 2003 specific and potent NS3 
protease hepatitis C virus inhibitor (BILN 2061) was designed by this method.
[117]
 In 
the beginning of 2004 it was reported the discovery of singe amino acid substitution 
in active site of this protease resulted in appearance of BILN 2061-resistant 
mutant.
[118][119]
 It may hope that protein-protein inhibitors would be more resistant for 
such mutations. Design of antibiotics which bind at active site of enzyme of pathogen 
organisms can be limited by high structural similarity between the host and the 
pathogen enzymes, whereas the greater structural variability of protein-protein 





some cases designed protein-protein inhibitors can be more selective than inhibitors 
of other classes. So experimental screening of molecular database results in 
identification of several compounds that selectively block interaction between 
phosphoprotein phosphatase, calcineurin, and NFAT (nuclear factor of activated T 
cells). The traditional method of calcineurin-NFAT inhibition consists in application 
of immunosuppressive compounds (cyclosporin or FK506) that inhibit calcineurin 
activity towards all its substrate.
[121] 
However the development of protein-protein 
inhibitors as potential drugs meets several difficulties that are common for all drugs 
(high activity, selectivity, etc) and can be specific for the given class of inhibitors. 
Specific difficulties are determined by structure of protein–protein interfaces and 
include relatively large surface shape of protein-protein interfaces, lack of cavity in 
these interfaces suitable for ligand accommodation, high binding affinity of subunits. 
However, shape of protein interfaces can be quite compact. Furthermore, covering of 
all protein contact surface by small compounds does not represent obligate 
requirement for protein-protein inhibitors. The most binding energy of protein-protein 
interaction is concentrated at several amino acid residues (hot spots) that are often 
located on the part of interface surfaces.
[122]
 So protein-protein inhibitors can occupy 
such hot spot, modify surface properties of the interface surface and thus preventing 
protein complex formation. The flat surface of protein–protein interface often tends to 
be overestimated when discussing the difficulties of protein-protein inhibitors design. 
The main challenge in discussion of protein-protein inhibitors perspective is high 
affinity of protein–protein interactions. Indeed the affinity of protein–protein 
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interaction depends on their function in cells and the Kd values for protein-protein 
complexes are within the range 10
-4
 – 10-14 M. So this range is close to 
enzyme-inhibitor affinity. In several cases it is sufficient for partial inhibition required 
for manifestation of significant biological effect by disrupting cascade amplification 
in sequential biochemical reactions and interactions. It is proposed that mechanism of 
such inhibitors would consist in two steps. At first inhibitor reversibly binds to protein 
in position that facilitates covalent bond formation of the reactive group with amino 
acid residue of binding site at the second step. The ability of such approach was 
shown by designing inhibitors of dimerization to HIV protease and SH2 
domain.
[126][127]
 The designed molecules form disulphide bridges between drugs and 
cysteine located at protein interface surfaces. Thus, in many cases these putative 
difficulties of protein-protein interaction inhibitor development can be overcome and 
at present there are many small compounds that can disrupt different protein–protein 
interactions by forming a stable complex with the protein subunits on their contact 
interfaces. 
1.4 Screening technology for developing small molecule 
inhibitors for protein- protein interaction 
1.4.1 Inhibitors screening for BRCT domains with small molecule 
microarray 
Microarray-based technologies were originally introduced by Fodor et al in 1991 in 
the beginning of peptide microarray.
[128]
 In 1995, Schena et al. firstly created the very 
highly popular DNA microarray.
[129]
 Small-molecule and protein microarrays were 
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subsequently developed by MacBeath et al and at the first time, the array-based 
detection of kinase activity using peptide substrates was at the same time also 
demonstrated.
[130][131]
 In essence, these pioneering studies set the precedent for 
development of various types of microarray-based enzyme assays capable of sensitive 
characterization of different enzyme classes. At present, four key microarray-based 
platforms, namely protein, peptide, small molecule and cell based microarrays, have 
been already developed for catalomics or the high-throughput study of enzymes. 
Irrespective of the platform type, a capture, or bait molecules (such as proteins, 
peptides or small molecule and so on) are immobilized on the substrate, and then 
substrate in a solution are incubated on the microarray. With the activity or interaction 
between the bait molecules and substrate, the microarray fingerprints are generated 
based on the activity, or based different types of interaction for microarray application, 
such as protein–DNA interaction, protein–protein interaction, protein–lipid interaction, 
protein–peptide Interaction, protein–small-molecule interaction, Protein–RNA 
Interaction, protein–glycan Interactions. [132][133][134][135][136][137][138][139][140][141] 
1.4.1.1 Small molecule microarray 
High-throughput and general binding assays may provide a path for discovering small 
molecules that targets interesting proteins. One such binding assay involves small 
molecule microarrays (SMMs). SMMs is a subclass of microarrays which 
encompasses molecules of low molecular weight. Small molecules provide 
efficacious handles in the selective perturbation of cellular signaling and protein 




Microarray is a miniaturised array of molecules coated on a surface, usually glass 
slides. It offers collections of synthetic libraries and is a powerful and convenient 
technique designed for screening against targets of interest, such as specifically 
individual proteins, for discovery of potent and selective inhibitor. The key 
advantages of this strategy are the attainable high throughput screening, automation, 
parallelization and consumption of low quantities of samples. SMMs have matured 
into a robust and valuable platform for rapid large-scale screening and quantitative 
determination of protein-ligand interaction. 
1.4.1.2 Fragment based combinatorial library 
Fragment-based approach of combinatorial chemistry is one of the synthetic strategies 
developed to create various types of molecular libraries for microarray 
application.
[144][145][146] 
Combinatorial chemistry is the generation of large libraries of compounds with all the 
possible combination of the building blocks of chemical structures.
[147][148][149]
 
Fragment-based approach is one which facilitates the identification of fragments that 
bind to the target thereby conferring greater selectivity to a lead molecule. Generally, 
the molecules of libraries contain a tag which enables the molecules to be 
immobilized on the array, a linker which projects the molecules away from the surface, 
and a diversity head, which is the compound of interest designed according to their 
targets, sometimes are the small molecules.
[150]
 By introducing this concept, our 
platform was able to cover a large peptide-small molecule chemical space with a 
manageable number of libraries, without the loss of detailed and subtle information on 
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protein-protein interaction. This strategy had been adopted by our group using 
peptide-small molecule with a 243-member N-terminal library and a 50-member 
C-terminal library to identify a small molecule protein-protein interaction inhibitor for 
14-3-3 proteins. This was done by reconstitution of the most potent N- and C- 
terminal hits from microarray screens. 
1.4.1.3 Solid phase peptide synthesis 
Solid phase peptide synthesis methodology, introduced by Merrifield in 1963, paved 
the way for solid-phase combinatorial approaches.
[151]
 It is a process by which 
chemical transformations can be carried out on solid support in order to prepare a 
wide range of synthetic compounds. It has been widely implemented for hit discovery 
and lead optimization owing to its simplicity of use as well as advantages. The solid 
support can be used to compartmentalize library members, permitting the use of 
split-pool synthesis.
[152]
 The use of radiofrequency (Rf) tagging as the non-chemical 
tracking method and the IRORITM directed sorting technology for the split & pool 







Figure 1.7 IRORI TM technology. (A) 
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Schematic representation of a microkan reactor. (B) Combinatorial synthesis using directed sorting. 
(C) Decoding table of (B). 
 
1.4.2 Inhibitors screening for BRCT domains with fluorescent 
polarization assay 
Fluorescence polarization (FP) assay was based on the phenomenon that the 
fluorescence of a FP probe will be polarized when the probe binds the target proteins 
and then has different rotation. FP usually was designed and synthesized based on the 
known inhibitor or substrate of studied proteins.
[153]
  
1.4.2.1 Fluorescent polarization assay 
When a fluorescent molecule is excited with plane polarized light, light is emitted in 
the same polarized plane, provided that the molecule remains stationary throughout 
the excited state (which has the duration of 4 nanoseconds for fluorescein). If the 
molecule rotates and tumbles out of this plane during the excited state, light is emitted 
in a different plane from the excitation light. If vertically polarized light is exciting 
the fluorophore, the intensity of the emitted light can be monitored in vertical and 
horizontal planes (degree of movement of emission intensity from vertical to 
horizontal plane is related to the mobility of the fluorescently labeled molecule). If a 
molecule is very large, little movement occurs during excitation and the emitted light 
remains highly polarized. If a molecule is small, rotation and tumbling is faster and 




Figure 1.8 Fluorescent polarization working mechanism. a) Polarized light for 
different fluorophore. b) Fluorescent polarization machine mechanism. c) Working 
process for ligand binding with target protein.   
1.4.2.2 Application for fluorescent polarization assay 
FP-binding assays can, in principle, be used quantitatively to analyse binding of any 
small soluble fluorescent molecule (and any soluble ligand that competes with it) to a 
larger soluble protein. The suitability of FP assays to high-throughput screening, using 
relatively inexpensive equipment, has led to their use in screening programmes in 
drug discovery and as „off-the-shelf‟ assay kits for a variety of biomolecules. The 
former include development of inhibitors of interactions between proteins and either 
small molecules or other proteins.
[154][155][156][157][158][159]
 Use of FP to detect 
antibody-antigen interactions has provided many opportunities to adapt FP assays for 






Figure 1.9 Fluorescent polarization of screening different ligands for target protein. 
 
1.4.3 Inhibitors screening for BRCT domains with thermal shift 
assay by real-time PCR 
Thermal shift assay, also called Differential Scanning Fluorimetry (DSF) is a 
thermal-denaturation assay that measures the thermal stability of a target protein and a 
subsequent increase in protein melting temperature due to the binding of a ligand to 
the protein.
[165] 
1.4.3.1 Theory of the thermal shift assay 
The theory behind the assay is based on monitoring protein melting profiles (Figure 
1.10). Correctly folded proteins exhibit unfolding with an increase in temperature, 
resulting in exposure of hydrophobic regions and eventual protein aggregation.  
Ligand binding to a target protein can stabilize a protein's native state reflected in the 
increased melting temperature (Tm) of the bound protein. Measurement of the 
difference in melting temperatures of unbound and ligand-bound proteins can enable 
determination of ligand binding affinity constants.  The assay involves monitoring 
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changes in the fluorescence signal of SYPRO orange dye as it interacts with a protein 
undergoing thermal unfolding. The dye‟s fluorescence signal is quenched in the 
aqueous environment of a properly folded protein in solution, but becomes 
unquenched when exposed to the protein‟s hydrophobic core upon unfolding. The 
midpoint (Tm value) of the protein melting curve will increase in the presence of 
ligands that bind more tightly to the protein‟s native state than the unfolded state. 
 
Figure1.10 Thermal shift assay working mechanism 
 
1.4.3.2 Application of the thermal shift assay 
Thermal shift assay is also useful for comparing the relative stabilizing effects of 
protein ligands. For example, Fedorov et al. employed thermal shift assay to 
characterize the inhibitor binding profile of 60 Ser/Thr kinases by screening these 
proteins against a library of 156 validated kinase inhibitors.
[166]
 These experiments 
included compounds used in clinical trials and, interestingly, a surprising degree of 
cross reactivity was found for compounds that were previously thought to target 
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specific kinases. Carver et al. used thermal shift assay to decrypt the biological 
function of an unknown protein by screening 3000 compounds specifically selected to 
provide information about possible biological function, and identified the protein as a 
nucleoside–keto-sugar amino transferase. 
 
Figure1.11 Thermal shift assay of screening different ligands for target protein. 
1.4.4 Inhibitors screening for BRCT domains with isothermal 
titration calorimetry(ITC) 
Isothermal titration calorimetry (ITC) is now routinely used to directly characterize 
the thermodynamics of biopolymer binding interactions and the kinetics of 
enzyme-catalyzed reactions.
[167]
 ITC is a quantitative technique that can determine the 
binding affinity (Ka), enthalpy changes (ΔH), and binding stoichiometry (n) of the 
interaction between two or more molecules in solution. From these initial 
measurements, Gibbs energy changes (ΔG) and entropy changes (ΔS) can be 




1.4.4.1 Isothermal titration calorimetry(ITC) 
An isothermal titration calorimeter consists of two cells, a sample cell and a reference 
cell, made up of efficient thermal conducting material, surrounded by an adiabatic 
jacket. A syringe is used to titrate the ligand into the sample cell containing the 
biomolecule. Sensitive thermopile or thermocouple circuits are used to detect 
temperature differences between the two cells, while maintaining isothermal 
conditions between them (ΔT=0). During the titration process, heat change in the 
sample cell is observed. The power required to maintain isothermal conditions 
between the two cells, is measured by a calorimeter.
[168]
 A plot of power (μcals-1) 
against time (min) shows a series of peaks of heat flow (power) (Figure 2A). The area 
under the peaks gives the enthalpy (ΔH) of binding. A binding isotherm obtained from 
the plot of heat of formation against the molar ratio of ligand to biomolecule, gives 
information about the enthalpy (ΔH), the association constant (Ka) and the 
stoichiometry (n) of binding, which can be used to calculate changes in entropy (ΔS) 




Figure 1.12 Isothermal Titration Calorimetry working mechanism 
Isothermal Titration Calorimetry can measure Ka values between molecules ranging 
from millimolar to nanomolar range. Displacement or competitive binding methods 
need to be performed for ligands having binding affinities in nanomolar to picomolar 
range. In this method, a strong ligand is titrated with a mixture of biomolecule and 
weak ligand. The binding affinity of the strong ligand is found to decrease on 





Figure 1.13 Isothermal Titration Calorimetry for ligand with protein. 
Isothermal Titration Calorimetry is fast becoming a major tool in drug discovery 
studies. It is typically used as a secondary screening technique, to eliminate false 
positive hits after primary screening. Moreover, it is utilized for hit selection, lead 
optimization and validation of computational estimates of binding energetics. It is also 
used in binding studies (drug–macromolecule, drug–DNA/RNA, protein–protein 
interactions), where the binding mechanism, forces involved in binding and strength 
of the interaction can be analyzed.
[171][172]
 In conjunction with chromatography, ITC 
can be used to identify and isolate unknown target proteins including receptors and 
cell/tissue lysates. ITC provides insights into the SAR for ligand interaction with the 
target. This information is imperative in drug design and lead optimization. Using 
structural and thermodynamic information of binding, lead compounds can be further 
optimized. ITC is also gaining popularity as one of the methods for studying enzyme 
kinetics. It provides invaluable data on the kinetics and thermodynamics of enzyme 




1.4.5 Application for the small molecular inhibitor converted to 
cell-permeable probe for live cell imaging 
1.4.5.1 Reverse design from small molecule inhibitor to probe 
One application of small molecules inhibitors is converted to the cell-permeable probe, 
the probes that are described herein are substrates to the target enzyme, in chapter 2 
we design selectively probes for related cysteine cathepsins base on microarray 
screening results. We base the design on the structures of highly potent and selective 
cathepsin inhibitors which have undergone extensive medicinal chemistry 
optimization and thus display favourable pharmacokinetic properties in addition to 
potency and selectivity against related proteases.
[175][176]
 These inhibitors commonly 
carry a reactive group (often a nitrile group)as an electrophilic mimic of the 
substrate6s scissile bond. Once bound to a cathepsin, the electrophilic group is 
attacked by the catalytic cysteine residue of the enzyme, resulting in a covalent 
protein–inhibitor complex.[177][178] Since the catalytic mechanism is conserved within 
the cysteine cathepsin family, the selectivity of such inhibitors is most likely derived 
from their chemical scaffold. 
1.4.5.2 Cell-permeable probe for live cell imaging 
FRET is a non-radiative transfer of energy between two fluorescent molecules, the 
donor fluorescent molecule and the acceptor fluorescent molecule. If FRET happens, 
fluorescence of the donor molecule is decreased while the fluorescence from the 
acceptor molecule is observed. And if the acceptor molecule is a quencher, the whole 
probe will be weakly fluorescent because of the FRET. To achieve efficient FRET, the 
 32 
 
spectral overlap, together with the distance between the acceptor and the donor is 
important. FRET based probes have wide usage in the field of chemical biology 
because of their low background and easy design. In 2005, Bogyo and coworkers 
developed a quenched probe by using BODIPYL as the fluorophore and QSY7 as the 
quencher.
[179]
 This probe also contained an acyloxyl methyl ketone (AOMK) reactive 
group, which can form a covalent bond with the targeted proteins, papain-family 
cysteine proteases. In 2012, Yao and coworkers develop a microarray immobilized 
with 105 aldehyde-containing small molecules against mammalian cell lysates 
overexpressing cathepsin L to identify two potent inhibitors, which were subsequently 
converted into cell-permeable probes capable of live-cell imaging of endogenous 





Figure 1.14 Selected FRET based probe for protein imaging. 
1.5 Project objective 
The main aim of this study was to use the microarray platform to screen small 
molecular library, and find the best small molecular inhibitor for the protein-protein 
interaction. The specific objectives of this research were to: 
1. Propose to use the microarray platform to screen the small molecular library to 
find the best small molecular inhibitor for the protein-protein interaction. 
2. Investigate the small molecular inhibitor mechanism of protein, and discover 
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the natural configuration of the small molecular inhibitor and the target protein 
by using FP, thermal shift assay and ITC techniques. 
3. Investigate the FRET based probe that can be used of cell image for discover 
the endogenous protein function.   
The results of this present study may have significant impact on the development of 
the small molecular inhibitor, even the drug candidate in the research of cancer cell.  
And this method could provide new avenues for exploring novel therapeutic strategies 
for target protein: 
1. The microarray platform offers high-capacity, high-throughput screening tool 
for discovering the small molecular inhibitor for the protein-protein interaction. 
Microarray techniques have many advantages: time-saving, efficiency and 
repeatability. 
2. This method develops the more effective strategy for discovering the inhibitor 
for the protein, compared with the traditional method such as natural product 
synthesis.  
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Microarray-guided discovery of two-photon (2P) 
small molecule probes for live-cell imaging of 
















A microarray immobilized with 105 aldehyde-containing small molecules was 
screened against mammalian cell lysates over-expressing cathepsin L to identify two 
potent inhibitors, which were subsequently converted into cell-permeable probes 
capable of live-cell imaging of endogenous cysteinyl cathepsin acitivities by 
two-photon fluorescence microscopy. 
2.2 Introduction 
Proteases are critically involved in a multitude of vital biological processes, ranging 
from cellular signaling to tissue homeostasis.
[181] 
Cathepsins, of which eleven are 
cysteine proteases, reside mostly in endolysosomal vesicles and hydrolyze peptides 
and proteins destined for these compartments.
[182][183]
 The over-expression of these 
enzymes has been implicated in a number of pathological conditions. Consequently, 
the development of cell-permeable, small molecule probes capable imaging 
endogenous protease activities has gained considerable interest in recent years.
[184]
 Of 
the various enzyme-detecting, small molecule probes available, those amenable to 
two-photon fluorescence microscopy (TPFM) provide additional key advantages over 
the usual one-photon imaging techniques, as they can afford superior imaging results 
with increased penetration depth, lower tissue autofluorescence and reduced 
photodamage/photobleaching.
[185]
 In the context of live-cell bioimaging of cysteinyl 
cathepsins using small molecule probes, there are several reported examples.
[186]
 Their 
design principle is typically rational and involves taking a well-known 
substrate/inhibitor scaffold of a cysteinyl cathespin and introducing a suitable FRET 
 37 
 
(Förster resonance energy transfer) donor/acceptor pair or fluorogenic molecule. 
Two-photon (2P) small molecule probes for live-cell imaging of endogenous cysteinyl 
cathespins, however, are not presently available.
.[187]
 We sought to develop an 
alternative approach for high-throughput discovery of 2P small-molecule imaging 
probes against cysteinyl cathepsins using small molecule microarrays (SMMs).  
  SMMs are miniaturized assemblies of which compounds are spatially addressed in 
high-density grids, enabling simultaneous interrogation with suitable proteins and 
other biological targets. The platform offers a cheap and convenient method for rapid 
screening of thousands of compounds and has been successfully used in 
ligand/inhibitor identification, substrate fingerprinting and the profiling of cellular 
events.
[188]
 More recently, it has also been used for high-throughput discovery of 
activity-based probes.
[189][190]
 Herein, a microarray immobilized with 105 different 
aldehyde-containing small molecules were fabricated, and screened against lysates of 
mammalian cells over-expressing green fluorescent protein (GFP)-labeled cathepsin L 
(a key endolysosomal cysteinyl cathespin). Two potent inhibitors were identified and 
subsequently converted into the corresponding cell-permeable, 2P small molecule 
probes, which were then used to image endogenous cysteinyl cathepsin activities in 
live HepG2 cancer cells (Fig. 1). The general structure of our small molecule 
inhibitors is shown in Fig. 1B, in which an aldehyde warhead (WH) was strategically 
chosen because 1) it is a well-known reversible but tight-binding inhibitor motif of 
cysteine proteases, 2) could be readily synthesized using solid-phase chemistry, and 3) 
later facilitate the inhibitor-to-probe conversion (e.g. by linking a quencher molecule 
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via an amide bond). From previous literatures,
3 
it is known that cysteinyl cathespins 
prefer hydrophobic/aromatic P2 and P3 residues (based on standard protease substrate 
nomenclature), while variations at the P1 position are well-tolerated. Consequently in 
our small molecule library, a biotin-containing immobilization handle, Phe/Leu/Val 
residues and 35 different commercially available acid building blocks (aliphatic and 
aromatic) were installed at P1, P2 and P3 positions, respectively. Both P2 and P3 
building blocks were so chosen that the resulting compounds would possess 
reasonable cell permeability. We anticipated that, after SMM-guided identification of 
“hits”, the biotin moiety in the inhibitor moiety may be conveniently replaced with a 
suitable fluorophore (to afford the imaging probe) without compromising the 












Figure 2.1 (A) Overall strategy of the SMM-guided, high-throughput discovery of 
cell-permeable, 2P small molecular probes for imaging of endogenous cysteinyl 
cathepsins. (B) General structure of the 105-member small molecule library. Biotin is 
located at the P1 position. P2 consists of Phe/Leu/Val residues. P3 consists of 35 
different aromatic/aliphatic building blocks. Highlighted (in red) were the P2/P3 
structures of the two hits identified from the SMM screening results. 
2.3 Results and Discussion 
2.3.1 Synthesize of the 105 member library 
  The Synthesis of Fmoc-Lys(Mtt)-CHO was based on previously published 
procedures. AM-Resin (15.00 g, 7.50 mmol) was swelled in DMF for approximately 
30 min and then filtered. Fmoc-Gly-OH (4.0 eq., 8.90 g, 30 mmol), and standard 
coupling reagents, HOBT (4.0 eq., 4.05 g, 30 mmol), HBTU (4.0 eq., 11.93 g, 30 
mmol) and DIEA (8.0 eq., 10.20 mL, 30 mmol) were dissolved in 150 mL of DMF. 
The mixture was added to the resin and the reaction was stirred overnight. The resin 
was washed nine times, alternating between DCM/DMF and then dried in vacuo. 
Fmoc was deprotected using a 20% piperidine solution (in DMF) for 2 h and the resin 
was washed and dried as before. A mixture of Fmoc-Thr(OtBu)-OH (4.0 eq., 11.93 g, 
30 mmol), HOBT (4.0 eq., 4.05 g), HBTU (4.0 eq., 11.93 g) and DIEA (8.0 eq., 10.20 
mL) dissolved in 150 mL of DMF was added to the Gly-Resin, and the reaction was 
stirred overnight. The resin was washed and dried as before. Fmoc deprotection was 
next carried out, followed by DCM/DMF washes. Subsequently, t-butyl deprotection 
was carried out with a 1:1 solution of TFA in DCM for 1 h. Upon further washes with 
DCM (3×), the resin was neutralized with 10% DIEA in DCM, followed by repeated 
washing with DCM (5×), DMF (5×) and MeOH (1×). Next, Fmoc-Lys(Mtt)-CHO (2.0 
g) dissolved in 1% DIEA/MeOH was added to the resin in a 60 
O
C oil bath. After 
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about 4 h, the resin was filtered, and washed 9 times with DCM/DMF, then dried in 
vacuo. A ninhydrin test for free amines tested negative and a chlorinyl test for a 
secondary amine tested positive to confirm the loading of the aldehyde.   
Boc2O (10.0 eq.) was dissolved in DMF and DIEA (20.0 eq.) and combined with 
the resin, and allowed to stir for 2 h, and then washed 9 times with DCM/DMF. Mtt 
deprotection was carried out with 1% TFA in DCM for 30 min. Deprotection was 
confirmed with a positive ninhydrin test. The resin was washed as usual with DCM 
and DMF. The deprotected resin was added to D-biotin (4.0 eq.), HOBt (4.0 eq.), 
HBTU (4.0 eq.) and DIEA (8.0 eq.) in DMF. The reaction was stirred overnight and 
then washed with DCM/DMF. A negative ninhydrin test confirmed that the free 
primary amine group was no longer present. The resin was split into three different 
flasks and a different P2 group was coupled overnight onto the resin in each of the 
flasks. In each flask, the standard couple reagents HOBT (4.0 eq.), HBTU (4.0 eq.) 
and DIEA (8.0 eq.) were dissolved in DMF in addition to Fmoc-AA-OH (4.0 eq.). 
The three different P2 groups used were Leucine, Valine and Phenylalanine. Again, the 
resin was washed and dried as before. Finally, the resin from each flask was further 
divided into 45 equal portions and placed into separate microreactors, with each 
holding ~40 mg of the resin, and coded with an Rf tag. Again, standard coupling 
reagents were used, with HOBT (4.0 eq.), HBTU (4.0 eq.) and DIEA (8.0 eq.) 
dissolved in DMF, and each of the 35 different acid building blocks. After the 
coupling completed, the resins were washed with DCM and DMF, and dried in vacuo.  
In total, 105 compounds were synthesized on the resin. The resin-bound 
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compounds were first separated into their own blue capped containers. Each container 
was added a ~1 mL of a deprotection cocktail containing 95% TFA and 5% TIS and 
the incubation was continued for 30 min. After a quick wash with DCM, 1 mL of a 
cleavage cocktail (acetonitrile/water/TFA = 60:40:0.1) was applied and the reaction 
was continued for 30 min at 60 
o
C. The microreactors were removed from the blue 
cap containers and the product was concentrated to give the crude products. All 
compounds were characterized by LCMS and all were shown to be of correct 
molecular weight and most (> 95%) with sufficient purity (> 80%). They were used 
directly for subsequent microarray experiments. Below are representative LCMS 
profiles of selected compounds. 
 
Scheme 2.1. Solid phase synthesis of the 105 aldehyde library. (a) i: 
Fmoc-Gly-OH/HBTU/ HOBt/DMF, 4 h; ii: 20% piperidine/DMF, 30 min; iii: 
Fmoc-Thr(OtBu)-OH/HBTU/DIEA/DMF, 4 h; (b) i: 20% piperidine/DMF, 30 min; 
ii: TFA/DCM (1:1) 1 h; iii: 10% DIEA/DCM. (c) 1% DIEA/MeOH, 2 h, 60
 o
C. (d) 
Boc2O, 1% DIEA/DCM, 2 h. (e) i: 1% TFA/DCM, 30 min; ii: 
Biotin/HBTU/DIEA/DMF, 4 h. (f) i: TFA/TIS/EDT (95:5:0.1); ii: ACN/H2O/TFA 















MW Exp MW Obs 




















0.0 2.5 5.0 7.5 10.0 12.5 15.0 min 
  
(214nm) 
200 400 600 800 1000 1200 m/z 
543.3037 
664.3309 
0.0 2.5 5.0 7.5 10.0 12.5 15.0 min 
214nm 






































































































































































































































































































































































































Table 2.1. Compound ID and the corresponding printing pattern. 
2.3.2  Gateway cloning and transfection 
The entry clone containing the Cathepsin L gene was from Human ORFenome 
Release 1 in the donor vector pDONR223. The LR reaction was performed using LR 
Clonase II using two different destination vectors (pDEST47 and pDEST53) 
following protocols provided by the vendor. The final constructs were named 
pDEST47-CTSL and pDEST53-CTSL, which contain C- and N-terminal GFP fusion, 
respectively. Gene size and sequence were confirmed again using PCR and DNA 
sequencing with attB1 and attB2 primers. Both the pDEST47-CTSL and 
pDEST53-CTSL were transiently transfected into HEK293T cells. Successful 
expression of the GFP-fused Cathepsin was confirmed by fluorescence microscopy 
and western blotting (Figure 2.3) using anti-GFP antibody (Santa Cruz, USA). 
(A)                                           (B) 
 
Figure 2.3 Cell image after transfection and western blot (A) One-photon excited 
fluorescence images of transfected HEK293T cells. (1) pDEST47-CTSL (C-terminal 
GFP fusion). Inset: negative control (no plasmid tranfected); (2) pDEST53-CTSL 
(N-terminal GFP fusion). (B) Western blotting analysis of cell lysates from 
experiments in (A). Lane 1: 10 µg lysates of HEK293T cells transfected with control 
GFP plasmid (expected protein MW: 27KD); Lane 2: 10 µg lysates of HEK293T cells 
transfected with pDEST47-CTSL (expected protein MW: 68KD); Lane 3: 10 µg 





2.3.3  Microarray preparation and Hit identification 
The microarray fabrication and compound immobilization were carried out following 
previously published protocols.
1
 To screen the compound-immobilized SMM, 15 L 
of the above cell lysate (pDEST47-CTSL), containing over-expressed Cathepsin L, 
was added to 60 L of a NaOAc buffer (0.1 mol sodium acetate, pH 5.5, 1 mM EDTA 
and 4 mM dithiothreitol) to activate the enzyme. After 30 min, 15 L of 0.1% Tween 
20 in NaOAc buffer and 60 L NaOAc buffer was added. Using a micropipette, 
approximately 40 L of this mixture was spread overtop the slide, in the sections were 
the compound had been printed. After 1.5 h, the mixture was washed off with 
deionized water and the slides were scanned under the Typhoon9410 fluorescence 






Figure 2.4.  Microarray results after screening 105 aldehyde library and spotting 
pattern. 
2.3.4  IC50 evaluation hits against recombinant Cathepsin L 
IC50 measurements were performed to determine the potency of two identified hits 
D02 and D17 against commercially available recombinant Cathepsin L. The 
dose-dependent inhibition assays were performed by varying the concentration of 
inhibitors under fixed enzyme and fluorogenic substrate Z-FR-AMC (Biotium) 
concentrations of 5 nM and 10 nM, respectively. The fluorometric assays were 
performed in 384-well Greiner black plates, and the fluorescence readouts were 
monitored over 1.5 h assay runs using BioTek Multi-Mode Microplate Reader for 
fluorescence background at λex/λem = 360/460 nm. Kinetic endpoints were obtained 
and analyzed using GraphPad Prism software to plot out the IC50 graphs (Figure 2.5). 
D15 D23 TMR 
B07 B15 B23 D07 D15 D23 TMR 
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Figure 2.5. IC50 evaluation of D02 and D17 against Cathepsin L.  
2.3.5  Synthesize of the chemical probes ZK-1 and ZK-2 
  Subsequently, these two potent small molecule inhibitors were converted into 
imaging probes based on our earlier described design principle (Figure 2.1). As the P1 
residue in the inhibitors did not play a significant role in binding to cathepsin L, and 
the aldehyde WH sat at where the scissile bond of a cysteinyl cathepsin substrate 
would have been located, we replaced the biotin moiety in D02/D17 with a 
two-photon dye, DL-1 (an 4,6-bis(4-hydroxystyryl)pyrimidine derivative), and the 
aldehyde WH with Disperse Red 1 (DR-1; a fluorescence quencher) linked to the P1 




Scheme 2.2 Structures of hits identified and their synthetic scheme. (Red) DL-1. 
(Blue) DR-1. 
2.3.6  Optical property and bioimaging for probes ZK-1 and ZK-2 
We next evaluated whether the proteolytic cleavage and fluorescence increase of 
ZK-1 and ZK-2 in the presence of cysteinyl cathepsins could be monitored 
spectroscopically. Mammalian lysates from HepG2 cells (a liver cancer cell line 
known to over-express endolysosomal cysteinyl cathepsins) were used as the enzyme 
source. As shown in Fig. 3A, a time-dependent proportional increase in fluorescence 
(max λem = 522 nm) was observed, evidently due to successful proteolytic cleavage of 
the probes and release of the quencher. Finally, we examined whether the probes 
could be used in live-cell imaging experiments to detect endogenous cysteinyl 
cathepsin activities (Figure 2.6); HepG2 cells treated with either ZK-1 or ZK-2 for 2 
h showed exclusive fluorescence (green channel) in endolysosomal compartments 
which were readily stained by Lyso Tracker™ (red channel).12 The same cells 
pre-treated with E-64 (a broad-spectrum cysteinyl cathepsin inhibitor) showed no 
detectable fluorescence in the probe channel, indicating these fluorescence signals 
were a direct result of endogenous cysteinyl cathepsin activities.  



































































   
Figure 2.6 (A) Time-dependent emission spectra (λem = 522 nm) of ZK-1/-2 in HepG2 
lysates (Hepes buffer, pH 5.5) at room temperature. (B) Two-photon confocal images 
of live HepG2 cells upon treatment with ZK-1/-2 (2 µM) for 2 h. Probe channel 
(pseudo-colored in green): em = 550 nm. Tracker channel (pseudo-colored in red): 
em = 590 nm channel. Endolysosomal tracker (LysoTracker® Red DND-99; 
Invitrogen) was used. In panels where a general cysteine protease inhibitor (E64) was 
used, HepG2 cells were preincubated with 15 µM of E64 before probe treatment and 
imaging. All images were acquired under the same settings. 
2.4 Conclusion 
  In conclusion, by using a small molecule microarray as a high-throughput 
screening platform, we have successfully discovered two potent inhibitors of 
cathepsin L which were converted strategically into the corresponding two-photon 
small molecule imaging probes, both of which were found to be cell-permeable 
and could detect endogenous cysteinyl cathepsin activies from cell lysates or live 
mammalian cells of HepG2 cancer cells. Future extension of this approach will 
focus on developing imaging probes that can distinguish different cysteinyl 
cathepsins.    
 
(B) Bright field Probe Tracker 
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  BRCTs are phosphoserine-binding domains found in proteins involved in DNA 
repair, DNA damage response and cell cycle regulation. BRCA1 is a BRCT 
domain-containing, tumor-suppressing protein expressed in the cells of breast and 
other human tissues. Mutations in BRCA1 have been found in ~50% of hereditary 
breast cancers. Cell-permeable, small molecule BRCA1 inhibitors are promising 
anti-cancer agents, but are not available currently. Herein, with the assist of 
microarray-based platforms, we have discovered the first-ever cell-permeable 
protein-protein interaction (PPI) inhibitors against BRCA1. By targeting the (BRCT)2 
domain, we showed compound 15a and its prodrug 15b inhibited BRCA1 activities in 
tumor cells, sensitized these cells to ionizing radiation-induced apoptosis, and showed 
synergistic inhibitory effect when used in combination with Olaparib (a small 
molecule inhibitor of poly-ADP-ribose polymerase) and Etoposide (a small molecule 
inhibitor of Topoisomerase II). Unlike previously reported peptide-based PPI 
inhibitors of BRCA1, our compounds are small molecule-like and could be directly 
administered to tumor cells, thus making them useful for future studies of 
BRCA1/PARP-related pathways in DNA damage and repair response, and in cancer 
therapy. 
3.2 Introduction 
  Phosphorylation-dependent protein–protein interactions (PPIs) control important 
cell signalling pathways.
[191]
 They are tightly regulated by kinases, phosphatases, and 
a large number of proteins containing phosphopeptide-binding domains, including 





 Among them, BRCTs are phosphoserine (pSer)-binding 
domains commonly found in proteins involved in DNA repair, DNA damage response 
and cell cycle regulation.
[194]
 One of the best-known BRCT domain-containing 
proteins is BRCA1 (breast cancer type 1 susceptibility protein), which is a 
tumor-suppressing protein expressed in the cells of breast and other human tissues.
[195]
 
BRCA1 is a large, modular protein of 1,863 residues containing an N-terminal RING 
domain, a central region and two C-terminal tandem BRCT domains. The BRCT 
repeats recognize and bind to a variety of phosphorylated proteins including BACH1 
(a DNA helicase), Abraxas, CtIP and others.
[196]
 Together, these PPI complexes play a 
key role in the DNA damage and repair response. Mutations in BRCA1, including 
those within its BRCT domains, have been found in ~50% of hereditary breast 
cancers.
[197]
 It is now well-known that cancer cells with truncations in the C-terminus 
of BRCA1 are sensitive to DNA damage-based therapeutics.
[198]
 Therefore, 
cell-permeable, small molecule PPI inhibitors targeting the BRCT domains of 
BRCA1 are highly promising, potential anti-cancer agents.
[199]
 Currently, no such 
agents are available. The only known BRCA1 (BRCT)2 inhibitors known in the 
literature, to our knowledge, are phosphopeptide-based compounds developed 
recently by Natarajan and coworkers, but they were not cell-permeable, and required 
conjugation to cell-penetrating peptides for cellular uptake.
[200] 
Each BRCA1 BRCT domain consists of approximately 90-100 amino acids that 
adopts a characteristic fold containing a central four-stranded β-sheet and three 
α-helices packed along the opposite faces of the sheet (Figure 1a);[201] for the 
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BRCA1/BACH1 complex, the two BRCT repeats stack against each other in a 
head-to-tail manner, in which the N-terminal half of one BRCT domain forms the 
pSer990-binding pocket, while the C-terminal half of the same domain provides a 
hydrophobic binding pocket for Phe993 (e.g. the P+3 residue in BACH1 
phosphopeptide; Figure 1a). Most mainstream pharmaceutical targets, such as 
enzymes and receptors, are considered “druggable” due to the presence of highly 
compact and well-defined active sites or pockets in these proteins that are amenable to 
small molecule binding. BRCA1 on the other hand, is generally considered 
“un-druggable”. The most viable option for BRCA1 inhibition therefore is to develop 
PPI inhibitors that target its BRCT domains. This is however considered a highly 
challenging endeavour, as most small molecules, due to their limited sizes and 
functional groups, do not provide sufficient enthalpy needed to bind tightly to the 
much larger protein-protein interface.
[202]
 As such, most known PPI inhibitors are 
peptide-based and normally possess poor cellular activities (e.g. permeability and 
stability).
[203][204] 
We recently developed a small molecule microarray (SMM) capable 
of rapid identification of small molecule PPI inhibitors.
[205]
 As highly miniaturized 
screening platforms of immobilized small molecules (i.e. > 1000 compounds on a 
single 2.5 x 7.5 cm glass slide), SMMs are especially suitable for screening of novel 
PPI inhibitors,
[206]
 as few other assays, including those based on fluorescence 
polarization, isothermal titration calorimetry (ITC), protein stability shift and surface 
plasmon resonance (SPR), can provide the type of generality, throughput and 
sensitivity with minimal consumption of precious proteins.
[207]
 By using what we 
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called a fragment-based combinatorial approach,
[208]
 we were able to convert a 
peptide-based PPI inhibitor of 14-3-3 proteins into cell-permeable small molecules 
through the construction/screening of peptide-hybrid SMMs.
[209]
 In the current study, 
we have adopted this strategy in the study of BRCA1 protein, and successfully 
discovered the first-ever cell-permeable small molecule inhibitor, e.g. compound 15 
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Figure 3.1. a) Crystal structure of BRCA1 BRCT repeats (shown in blue and red 
ribbons) bound to BACH1 phosphoopeptide (PDB ID: 1t29). The BACH1 peptide 
sequence is ISRSTpSPTFNKQ, with two critical residues shown in sticks (right 
inset). b) Workflow of the microarray-assisted discovery of cell-permeable small 
molecule PPI inhibitors of BRCA1 (BRCT)2 domains. c) Structure of compound 15. 
(right) Docked complex of 15 bound to the pSer-binding pocket of BRCA1 (BRCT)2 
domains. 
3.3 Reuslts and discussion 
3.3.1 Protein expression and purification 
 62 
 
His-tagged fusions of different human BRCT plasmid constructs (e.g. DNTT, POLM) 
were obtained by standard molecular cloning using Ligation Independent Cloning 
(LIC). GST-tagged fusion of human BRCA1-(BRCT)2 was kindly given by Smerdon 
group. 14-3-3 protein was obtained as previously described. All expression constructs 
were transformed into an E. coli. BL21(DE3) strain. Overnight cultures were diluted 
1:100 in LB media supplemented with 100 μg/mL of ampicillin and grown at 37 °C. 
At OD600 ~0.6-0.8, expression was induced by addition of 0.1 mM of IPTG 
(isopropyl-n-D thiogalactopyranoside) and cultures were grown further at 18 °C 
overnight. The fusion proteins were soluble, expressed in high yields and the 
expression was verified by coommassie blue staining. After cell harvest and lysis (20 
mM Tris-HCl, 150 mM NaCl, 0.2 mM DTT, pH 7.4) by sonication (6X pulses of 15 s 
each at half maximal power, on ice), the solution was clarified by centrifugation at 
10000 g, 30 min, 4 °C and loaded onto a column containing 200 μL of His-tagged 
resin (Amersham Biosciences) pre-equilibrated with a column buffer (20 mM 
Imidazole, 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4). 
Following incubation for 20 min at 4 °C, the resin was washed 5 times with the 
column buffer and the fusion was eluted with elution buffer (200 mM Imidazole, 140 
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) or continuing 
to the next protein labeling step. GST-BRCA1-(BRCT)2 protein was similarly 
expressed, and purified by using standard GST purification protocols. For His-tagged 
proteins, continuing from the washing of resin with wash buffer, the resin was further 
washed twice with PBS buffer (pH 7.4). To the resulting resin, H2O, NaHCO3 (100 
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mM, pH 9.0) and Cy5-NHS ester were added. Following incubation on ice for 1 h, the 
unreacted dye was quenched with 3 M hydroxylamine (in 2.5 M NaOH) for further 30 
min. PBS was used to wash the labeled-resins five times to remove the excess dye. 
The protein was finally eluted with elution buffer (200 mM Imidazole, 140 mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4). Fractions containing the 
desired proteins were pooled and dialyzed onto Microcon® centrifugal filter device 
(cutoff: 3 KDa) and store at -20 °C with 20% glycerol added. To ensure successful 
protein labeling and purity, the labeled proteins were analyzed by separation on a 15% 
SDS-PAGE gel. 
BRCT domain protein Source Classification of Protein 
DNTT H.sapiens DNA polymerase 
POLM H.sapiens DNA polymerase 
BRCA1 H.sapiens Transcription regulatory protein 
Table 3.1. BRCT domain proteins used in the study 
 
 







Figure 3.2 Coomassie and Fluorescence gel for chosen BRCT domain 
3.3.2 Protein screening on the peptide microarray and analysis 
The labeled proteins were subsequently reconstituted in a final buffer volume of 












DNTT POLM BRCA1 
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GST-BRCA1-(BRCT)2 protein, the purified protein was fluorescently labeled based 
on previously reported protocols.
 
In a standard microarray experiment, the labeled 
protein (2 μM; 50 μL) was applied under coverslip to the array, as previously 
described.
 
In a dose-dependent experiment for Kd measurements, various 
concentrations of the protein (0.05 µM to 10 µM) were applied to different sub-arrays 
on the same slide, as previously described.
 
Slides were scanned using an Array 
microarray scanner installed with the relevant filters (Cy3: λex/em = 548/595 nm; Cy5: 
λex/em = 633/685 nm). Pro-Q™ staining was routinely carried out on spotted slides to 
ensure the consistency and quality of the slides.  
Microarray data was extracted by using the instrument-installed software, as 
previously described.
 
Values from duplicated points were background subtracted and 
averaged (Duplicated spots with a standard deviation > 0.2 were rejected). The dataset 
was presented as colored heatmaps, using the Treeview software 
(http://rana.lbl.gov/EisenSoftware.htm). Position specific scoring matrix analysis was 
performed using the software developed by Stephen Shaw (sshaw@nih.gov) and 
obtained and used with permission. Other data analysis was carried out with 
Microsoft Excel. All compounds were spotted onto the same slide where up to 3 
identical subarrays were generated on the same platform, allowing consistent/uniform 





Figure 3.3 ProQ™ image of the previously published 1000-member peptide 
microarray. The 1000 peptides were spotted in duplicate (vertical), washed and treated 
with ProQ and imaged under Cy3 channel. The image shows that most spots (> 99%) 
located on the array were spotted uniformly and consistently. 
 
    
Figure 3.4. Screening of the Cy5-labeled BRCA1-(BRCT)2 domain protein against 
the 1000-member peptide microarray (left). This image was reproduced in Figure 2 of 
the maintext. For comparison, Cy3-labeled 14-3-3 was run side-by-side on the same 




            
 
Figure 3.5. Relative binding potency of BRCA1-(BRCT)2 domain protein across the 
six permutated positions (left to right: in the order of P-3, P-2, P-1, P+1, P+2 and P+3), as 
obtained from the analysis of top-50 hits from both the N- and C-terminal 
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sub-libraries. Each bar represents the frequency of occurrence of a particular amino 
acid in the top 50 binders from each of the two sub-libraries. 












Scheme 3.1 Synthesis of peptide-small molecule hybrid libraries.  
The synthesis was performed by using standard Fmoc Strategy combined with 
IRORI
TM
 directed sorting technology, following previously published procedures.
 
For 
the N-terminal sub-library, Rink amide resin was used as the solid support. Standard 
HOBt/HBTU/DIPEA coupling method was used throughput the whole process. The 
HOBt/HBTU/DIPEA coupling method was proved to be the most ideal way to 
incorporate Fmoc-Ser[PO(OBzl)-OH]-OH. Each microreactor contains around 20 mg 
of rink amide resin and a unique RF tag for sorting application. The resin was swelled 
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in HPLC-grade DMF for 1 h at room temperature. Subsequently the Fmoc group was 
deprotected by treatment of 20% piperidine for 1 h at room temperature. Following 
removal of the piperidine, the resin was washed extensively with DMF and DCM. 
The microreactors were dried thoroughly in vacuo. After the first coupling of Fmoc- 
Lys(Biotin)-OH, any unreacted resin residue was capped with a solution of Ac2O (10 
eq.), DIPEA (20 eq.) in DCM, and the reaction mixture was allowed to react for 2 h at 
room temperature, followed by extensive wash with DCM and DMF. Subsequently 
the resin was deprotected with 20% piperidine again and ready for next coupling 
cycle. Repeat the above cycle until the last amino acid, Fmoc-Ser[PO(OBzl)-OH]-OH 
was coupled. Next, the microreactors were sorted and distributed into several reaction 
vessels, and each containing a unique acid building block (5.0 eq.), pre-activated with 
HATU/HOAt/DIPEA (1/1/2 ratio relative to the acid). The resins were swelled in 
DMF for 0.5 h before coupling. The coupling reactions were carried out for overnight 
at room temperature with shaking. At the end of coupling, the microreactors were 
collected and washed thoroughly with DMF and DCM. Final capping was done with a 
solution of Ac2O (10 eq.), DIPEA (20 eq.) in DCM , and the reaction mixture was 
allowed to react for 2 h at room temperature, followed by extensive wash with DCM 
and DMF.  
For the C-terminal sub-library, reductive amination was done in first step, 
following previously published procedures. PL-FMP resin was swelled in DCE for 2 h. 
Then DCE was removed, followed by the addition of the amine building block (4 eq.) 
solution in DCE and the reaction mixture was shaken for 2 h. Then HOAc (1%) and 
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Na(OAc)3BH (6 eq.) were added and the reaction mixture was shaken for further 16 h. 
The reaction was then decanted and the resulting resin was extensive washed with 
THF, MeOH, DCM, and dried in vacuo. The completeness of the reaction was 
monitored by chloranil test. To the resulting resin was added a pre-activated solution 
containing Fmoc-Ser[PO(OBzl)-OH]-OH (4.0 eq.), PyBrOP (4.0 eq.), and DIPEA 
(8.0 eq.) in DMF. The reaction mixture was shaken overnight at room temperature and 
the resin was washed with DMF and DCM extensively, and dried in vacuo. The 
completeness of the reaction was also monitored by chloranil test. Subsequently the 
resin was deprotected with 20% piperidine again and ready for next coupling cycle. 
Repeat the cycle using HOBt/HBTU/DIPEA coupling method until the last amino 
acid was coupled. Biotin-GG was attached at the N-terminus of peptides for future 
microarray immobilization. Final capping was done with a solution of Ac2O (10 eq.), 
DIPEA (20 eq.) in DCM , and the reaction mixture was allowed to react for 2 h at 
room temperature, followed by extensive wash with DCM and DMF.  
For compound cleavage, microreactors containing of both N- & C-terminal 
sublibraries were decoded first, then cleaved with a TFA cocktail (95% TFA, 2.5% 
TIS, 2.5% H2O) for 6 h at room temperature. Following prolonged concentration in 
vacuo until > 90% of cleavage cocktail was removed. Cold ether was added to the 
liquid residue to precipitate the peptides. The peptides were allowed to precipitate at 
-20
 o
C for overnight. The ether layer was discarded and the precipitates were dried 
thoroughly in vacuo. This ether precipitation process was repeated for a couple more 





C for future use. LCMS was performed to ensure the peptides were of correct mass 
and sufficient purity. Subsequent microarray work was carried out directly with these 
peptides without further purifications. 
3.3.4 Screen the peptide-small molecule library with protein and 
analysis 
The labeled proteins were subsequently reconstituted in a final buffer volume of 
80 μl PBS (pH 7.4) containing 1% bovine serum albumin (BSA). For 
GST-BRCA1-(BRCT)2 protein, the purified protein was fluorescently labeled based 
on previously reported protocols. In a standard microarray experiment, the labeled 
protein (2 μM; 50 μL) was applied under coverslip to the array, as previously 
described. In a dose-dependent experiment for Kd measurements, various 
concentrations of the protein (0.05 µM to 10 µM) were applied to different sub-arrays 
on the same slide, as previously described. Slides were scanned using an Array 
microarray scanner installed with the relevant filters (Cy3: λex/em = 548/595 nm; Cy5: 
λex/em = 633/685 nm). Pro-Q™ staining was routinely carried out on spotted slides to 
ensure the consistency and quality of the slides.  
By using dose-dependent experiments, as previously described, we extracted the 
binding data of BRCA1 BRCT domain against seven potential binders made of 
peptide-small molecule hybrids. The corresponding Kd was generated by fitting the 
data to the following equation, under the assumption that equilibrium is achieved 
during the incubation period:  
Observed Fluorescence of χ =  
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Saturation dynamics observed when plotting Observed Fluorescence against the 
applied Protein Concentration were fitted to the above equation using the Graph pad  
Prism software version 4.03 (GraphPad, San Diego, USA) revealing the binding 














































ID N08 N19 N22 N41 N51 C21 C22
Kd/µM 0.33  0.02 0.03  0.01 0.08  0.02 0.21  0.04 0.05  0.02 0.79  0.09 0.86  0.08  
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Figure 3.6 Screening of the 101-membe peptide-hybrid small molecule microarray 
with Cy5-labeled BRCA1-(BRCT)2. The library was spotted in duplicate (horizontal). 
(a) Image of the SMM upon ProQ treatment and scanned under Cy3 channel. The 
image shows that most spots (> 99 %) located on the array were spotted uniformly 
and consistently. For spotting format, please refer to Table S1. (b) 
Concentration-dependent screening of the microarray against Cy5-labeled 
BRCA1-(BRCT)2 domain (10, 5, 1, 0.5, 0.1, 0.05 M). (c) Selected panels/spots from 
Figure S5b, in which N19 was reproduced in Figure 2 of the maintext. 
Microarray-based Kd determination of selected Compounds were subsequently carried 
out, as previously described, and results are shown.  
 
Figure 3.7. Screening of the 101-membe peptide-hybrid SMM Microarray against 
two other Cy5-labeled BRCT Domains (e.g. DNTT and POLM). No significant 
binding was detected. 
 
Table 3.2 Microarray Spotting Pattern of the 101-Member Peptide-Hybrid SMM 




Scheme 3.2. (a) Synthesis of the 50-member, C-terminal extra-Glycine small 
molecule library (G1-50); See complete compound structures in SI_2 Appendix II. (b) 
Structures of “hit” compounds, identified from thermal shift assays, were further 
purified and renamed as 11-16.  
For the 50-member C-terminal extra-Gly small molecuale library (Scheme 3.2), 
synthesis was done as above described using PL-FMP resin. After reductive amination 
with 50 amine BB, the resulting resins were extensively washed, dried, then added a 
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pre-activated solution containing Fmoc-Gly-OH (4.0 eq.), PyBrOP (4.0 eq.), and 
DIPEA (8.0 eq.) in DMF. The reaction mixture was shaken overnight at room 
temperature and the resins were washed with DMF and DCM extensively, and dried 
in vacuo. The completeness of the reaction was also monitored by chloranil test. All 
subsequent coupling of Fmoc-Ser[PO(OBzl)-OH]-OH, (4.0 eq.) and N19 acid BB 
were done as above described. Upon cleavage off the resin, the resulting 50 
N19-containing small molecules were ether-precipitated as above described, 
concentrated, dissolved in 1 mL of DMSO and stored at -20 
o
C. Initial screening of 
these compounds without purification was carried out using RT-PCR thermal shift 
assay. Subsequently, selected “hits” were further purified by semi-preparative HPLC, 
characterized (by MS and NMR), and finally renamed as compounds 11-16. All other 
biological screenings were performed on these selected, purified compounds.  
 
Compound Tm Compound Tm Compound Tm 
G1 47.79±0.09 G18 48.64±0.04 G35 48.19±0.06 
G2 49.28±0.14 G19 48.70±0.05 G36 50.47±0.07 
G3 48.35±0.05 G20 49.50±0.03 G37 (15) 53.12±0.04 
G4 47.81±0.10 G21 46.27±0.18 G38 (13) 52.85±0.04 
G5 49.50±0.05 G22 47.71±0.07 G39 48.55±0.05 
G6 46.75±0.11 G23 48.17±0.05 G40 48.49±0.09 
G7 48.27±0.04 G24 (12) 52.31±0.08 G41 48.82±0.08 
G8 46.80±0.08 G25 47.83±0.18 G42 50.50±0.03 
G9 46.79±0.07 G26 50.31±0.03 G43 47.61±0.07 
G10 46.30±0.20 G27 46.97±0.09 G44 47.26±0.09 
G11 45.64±0.64 G28 46.92±0.08 G45 (14) 51.91±0.03 
G12 47.57±0.07 G29 46.94±0.07 G46 (11) 51.18±0.05 
G13 48.10±0.04 G30 48.34±0.08 G47 48.78±0.05 
G14 48.27±0.03 G31 48.20±0.06 G48 48.50±0.06 
G15 45.69±0.10 G32 50.48±0.08 G49 47.71±0.04 
G16 46.75±0.09 G33 49.50±0.05 G50 48.09±0.05 




Table 3.3 Thermal Shift Assay results of Tm graphs for the 50 extra glycine libraries (G1-50). 
Selected “hits” were renamed (in bracket) and highlighted (in yellow). 
3.3.6 Synthesis of “hit” small molecules  
 
Scheme 3.3 Synthesis of small molecule compound 1-10. 
For the small molecule “hit” compounds 1-10, reductive amination was done in the first 
step by following previously published procedures.
[1]
 PL-FMP resin was swelled in DCE for 
2 h. Then DCE was removed, followed by addition of the amine BB (C21 and C22; 4.0 eq.) 
solution in DCE and the reaction mixture was shaken for 2 h. Then HOAc (1%) and 
Na(OAc)3BH (6.0 eq.) were added and the reaction mixture was shaken for further 16 h. The 
reaction was then decanted and the resulting resin was extensive washed with THF, MeOH, 
DCM, and dried in vacuo. The completeness of the reaction was monitored by chloranil test. 
To the resulting resin was added a pre-activated solution containing 




reaction mixture was shaken overnight at room temperature and the resin was washed with 
DMF and DCM extensively, and dried in vacuo. The completeness of the reaction was also 
monitored by chloranil test. Subsequently the resin was deprotected with 20% piperidine 
again and ready for next coupling cycle. Using HATU (4.0 eq.)/DIEA (8.0 eq.), coupling was 
done with the acid BB (N08, N19, N22, N41 and N51), then the resulting products were 
cleaved with a TFA cocktail (95% TFA, 2.5% TIS, 2.5% H2O) for 6 h at room temperature. 
Following prolonged concentration in vacuo until > 90% of cleavage cocktail was removed. 
Cold ether was added to the liquid residue to precipitate the compounds at -20
 o
C overnight. 
The ether layer was discarded and the precipitates were dried thoroughly in vacuo. The entire 
precipitation process was repeated two more times. The resulting small molecules were 
purified by semi-preparative HPLC. 
3.3.7 Binding studies using fluorescence polarization(FP), real-time PCR 
thermal shift and Isothermal titration calorimetry(ITC). 
The BRCA1-(BRCT)2 domain FP assay was carried out in black 384-well microplates in 
a total volume of 20 µL in each well.
[2] 
For each assay, three basic solutions were prepared. 
The reaction buffer used in the FP assay throughout this study contains 16 mM Na2HPO4, 4 
mM NaH2PO4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, and 0.02% NaN3 at pH 7.3. 
Solution A contained a fluorescently labeled, known BRCA1-(BRCT)2 domain binding 
peptide, FITC-GG- SRSTpSPTFNK-CONH2 (purchased from GL Biochem), in the reaction 
buffer (solution with 2 µM of the peptide probe). Solution B contained the BRCA1-(BRCT)2 
domain protein in the reaction buffer (solution with 60 µM of BRCA1-(BRCT)2 domain). 
Solution C contained either a peptide-small molecule hybrid compound or a small molecular 
binder in 5% DMSO/H2O (with varied concentrations). Briefly, 17 µL of solution C and 2 µL 




µL of solution A was added. After 60 min of incubation at room temperature, the polarization 
values were measured using an Infinite F200 microplate reader (Tecan, Austria) installed with 
2 pairs of polarizers (λEx: 480 nm; λEm: 520 nm). The competitive effect was expressed as the 
percentage of control. IC50 values were determined from the model with nonlinear regression 
analysis, and summarized in Table S1.  
Thermal Shift Assay was determined using the Thermal Shift Assay Dye kit (Applied 
Biosystem, #4461146) following the manufacturer‟s guidelines. The BRCA1-(BRCT)2 
domain protein was added to a final concentration of 3 µM in the incubation buffer 
(contained 5 µL Protein Thermal Shift
TM
 Buffer, and 2.5 µL Protein Thermal Shift
TM
 dye). 
The final volume was 20 µL/well in an 384-well PCR plate. The temperature gradient was 
performed in the range of 30–80 °C, using a 7500 real-time PCR instrument from Applied 
Biosystems (Carlsbad, CA) with a standard ramp of 1% over the course of 60 min. The 
compound screening was performed at the 20 µM (in 5% DMSO) concentration of the test 
compounds. The detection of protein unfolding was performed with an excitation wavelength 
of 567 nm and an emission of 591 nm. 
ITC experiments were performed on an ITC200 calorimeter(GE Amersham) interfaced 
with a computer for data acquisition and analysis using Origin 7 software (Microcal Inc., 
Northampton, MA).
 
The protein was extensively dialysed against 20 mM HEPES, 100 mM 
NaCl, pH 7.4 and the same buffer was used for reconstituting small molecule ligands. The 
experiments were carried out by titration of 20 mM protein in the sample cell with 300 mM 
of ligand in the titration syringe. The cell was thermostated at 25 
o
C and uniform mixing was 
ensured by continuous stirring of titration syringe at 600 rpm. Protein and ligand samples 
were degassed and pre-incubated to 25 
o
C using ThermoVac (Microcal Inc.) and loaded into 
the calorimeter. All titration experiments were performed by addition of 2 µL titrant per 




only 0.3 uL of titrant and the corresponding enthalpy data point was deleted before the data 
analysis. The binding isotherms were best-fit to a one-set binding-site model by Marquardt 
non-linear least-square analysis to obtain binding stoichiometry (N), association constant (Ka), 
change in enthalpy (ΔH), and change in entropy (ΔS) using Origin 7.0 software (Microcal 
Inc). The free energy (ΔG) and ΔS were calculated by the following equations, respectively: 
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N08  - PVF 
 















0.41±0.08 52.11±0.07 20.17±1.08 0.50±0.03 
N51  - PVF 
 
0.20±0.04 53.22±0.16 38.87±2.51 0.26±0.02 
C21 RVF -  
 
1.29±0.09 48.91±0.13 8.89±0.34 1.12±0.04 
C22 RVF -  
 
1.31±0.07 48.56±0.14 7.74±0.51 1.29±0.08 
1  -  
 















2.19±0.27 48.17±0.10 1.76±0.33 5.88±1.10 
5  -  
 
1.33±0.12 48.64±0.08 1.78±0.22 5.70±0.71 
6  -  
 


















2.21±0.41 48.78±0.14 2.81±0.35 3.61±0.45 
10  -  
 





















































SRST - PTFNK SRSTpSPTFNK - - - - 
Blan
k 
- - - DMSO - 47.70±0.10 - - 
 
Table 3.3 Summary of FP, Thermal Shift and ITC Binding Data. 
3.3.8 cell culture and small molecule competition assay 
The HeLa cell line was cultured in growth media (DMEM supplemented with 10% fetal 
bovine serum, and 100 IU/mL penicillin). Cells were maintained in a humidified atmosphere 
of 5% CO2 at 37 °C. Cells were lysed in 50 mM Tris (pH 7.6) containing 150 mM NaCl, 5 




(Roche, Germany) with the 1 × PhosSTOP phosphatase inhibitors cocktail (Roche, Germany). 
Lysates were incubated with GSH beads containing equal amounts of immobilized 
GST-BRCA1-(BRCT)2 domain or GSH beads alone overnight at 4 °C with rocking. The 
beads were washed three times with PBS + 0.5% NP-40, resuspended in sample buffer, and 
analyzed by SDS-PAGE and immunoblotting. 
 
Figure 3.8 In-vitro inhibition assay for BRCA1-BACH1 interaction 
3.3.9 Cell proliferation and caspase assay 
Cell viability was determined using the XTT colorimetric cell proliferation kit (Roche) 
following manufacturer‟s guidelines.[4] Briefly, cells were grown to 20-30% confluence 
(since they will reach ~90% confluence within 24 h in the absence of compounds) in 96-well 
plates under the conditions described above. The medium was aspirated, washed with PBS 
(pH 7.4), and then treated, in duplicate, with 0.1 mL of the medium containing different 
combination of concentrations of the compound 15 and Olaparib. Staurosporine (STS, 200 
nM) was used as a positive control. Compound analogues were applied from DMSO stocks 
whereby the DMSO amount never exceeded 1% in the final solution. The same volume of 
DMSO was used as a negative control. After various treatment times, proliferation was 
assayed using the XTT colorimetric cell proliferation kit (Roche) following manufacturer‟s 
guidelines (read at A450-650 nm).  
      HeLa cells were grown to 50-60% in 6-well plates under the conditions described 
above. The medium was aspirated, and the cells were washed with PBS, then treated with 




50 µM Olaparib. Staurosprine (STS, 200 nM) was used as a positive control. After 24 h, cells 
were harvested with Trypsin, washed with PBS (pH 7.4), then lysed in 50 mM Tris (pH 7.4) 
containing 150 mM NaCl, 5 mM EDTA, 1% (vol/vol) NP-40, 2 mM DTT. Lysates were 
diluted to the same concentration by lysis buffer above. The lysates were analyzed by 
SDS-PAGE and immunobloting (anti-Caspase 3 (Ab-2, Oncogen) Mouse, anti-GAPDH 
(FL-335, Santa-Cruz Biotechnology) HRP). Furthermore, the activity assay was performed 
with caspase 3 fluometric substrate Ac-DEVD-AMC (#12-323, Upstate Biotechnology). 
Lysates and the substrate were mixed in the HEPES buffer (100 mM NaCl, 50 mM HEPES, 
10 mM DTT, 1 mM EDTA, 10% Glycerol, 0.1% CHAPS, pH 7.4). The lysate and substrate 
peptide concentration used in the assay were 1 mg/mL and 5 µM, respectively. The 
fluorescence readouts from the wells were measured using Tecan Infinite®200 microplate 
reader. 
 




























































Figure 3.9. Results of Cell Proliferation Assay. (A) XTT anti-proliferation different 
concentration of Compound 15, Olaparib and combination in different cell line (HeLa, 






cell lysate of Compound 15(50 µM), Olaparib(50 µM) , Combination, and STS(200nM, as 
the positive control) treated HeLa cell line for 24h. Cell lysate concentration (1 mg/mL final) 
and substrate concentration: Ac-DEVD-AMC (5µM). c) Detected the lysate above (DMSO, 
Compound 15 , Olaparib, Combination and STS cell lysate sample) by anti-Caspase 3.  
  
3.3.10 Hydrolytic stability assay 
The hydrolytic stability assay was carried out as previously described.HeLa cell lysates were 
prepared in the same buffer as above described, to a final 1 μg/μL concentration. Compound 
15 was added into the cell lysate (to a final concentration of 100 μM). At different time 
intervals, a small portion of the reaction was removed and filtered with a Microcon YM-3 
centrifugal filter device (Millipore), after which the remaining filtrate was immediately 
analyzed by LC-MS. 
 































































previously described.(* indicates compound 15, # indicates the dephosphorylated product). 
3.4 Conclusion 
In conclusion, with the assist of microarray-based screening platforms, we have successfully 
discovered the first-ever cell-permeable small molecule inhibitor against BRCA1, which is an 
important cancer-suppressing protein but considered “un-druggable”. By targeting the 
phosphopeptide-binding (BRCT)2 domain, we showed compound 15 conferred reasonable 
cancer cell-killing activities, and showed synergistic inhibitory effect when used in 
combination with Olaparib. Both in vitro and in-cell assays indicated inhibition of BRCA1 
cellular activities by 15 was caused by disruption of (BRCT)2-protein interactions. Unlike 
previously reported BRCA1 PPI inhibitors which are peptide-based and cell-impermeant,[10] 
15 could be directly administered to tumor cells. This critical feature will make 15 a useful 
chemical probe, together with other small molecule inhibitors of PARP, for future studies of 
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Microarray-guided Discovery of High-Throughput 
Identification of the Binding peptide for BRCT domain of 













The first small molecule inhibitor of PARP1 BRCT domain is reported. The binding motif 
peptide of PARP1 was investigated from two microarray libraries. Upon conjugation to 
fluorescence dye FITC, the resulting FITC labeled peptide was successfully introduced to set 
up the Fluorescence Polarization Assay. Development of a competitive, homogeneous, 
high-throughput fluorescence polarization (FP) assay to identify small molecule inhibitor of 
PARP1 BRCT domain is reported here. The FP assay was used for measuring binding 
affinities and inhibition constants of small molecule inhibitors of PARP1 BRCT domain. 
After screening the natural product library, small molecule 2-6 and Gossypol was found with 
the IC50 of 5.5 µM and 0.54 µM. 
4.2 Introduction 
The repair of DNA strand breaks is crucial for cell survival. In higher eukaryotes, cellular 
responses to DNA strand breaks are coordinated by a process called poly(ADP-ribosyl)ation 
(where ADP is adenosine diphosphate). This highly dynamic process begins with the 
hydrolysis of NAD+ (nicotinamide adenine dinucleotide) by poly(ADP-ribose) polymerases 
(PARPs), resulting in the polymerization of ADP ribose moieties onto a substrate protein. The 
most active PARP in DNA damage recognition, PARP1, is highly stimulated by single and 
double-strand breaks.
[211]
 Because it is a clinically important molecular target in the treatment 
of several cancers, including breast and ovarian cancers
[212]
, understanding how PARP1 is 
activated after binding DNA strand breaks is an ongoing challenge. 
The observation that poly(ADP-ribose) and PARP1 are critical for the repair of some DNA 
lesions
[213]
, as well as the ability of experimental PARP inhibitors such as 3-aminobenzamide 
to sensitize cells to the effects of DNA-damaging agents, stimulated the discovery and 
development of more potent and selective inhibitors of PARP1.
[214]
 Initially, it was thought 




could be used as radiosensitizing and chemosensitizing agents in oncology, but PARP1 
inhibitors also show promise for use as single agents now.
[215]
 To date, several PARP1 
inhibitors have reached early-stage clinical trials for various cancers, including olaparib 
(developed by AstraZeneca), veliparib (developed by Abbott), rucaparib(co-developed by 
Pfizer and Clovis), BMN‑673 (developed by Biomarin) and MK‑4827 (developed by Merck 
and Co.).
[216]
  The preliminary success of these drugs has demonstrated the potential of 
pharmacologically tar-geting PARPs and this has led to an increased interest in targeting 
other members of this superfamily. PARP1 is a nuclear protein comprised of three functional 
domains. The amino-terminal DNA-binding domain con-tains two zinc fingers that are 
important for the binding of PARP1 to single-strand breaks and double-strand breaks (DSBs). 
A third zinc finger was recently described and found to be dispensable for DNA binding, but 
is important for coupling damage-induced changes in the DNA-binding domain to alterations 
in PARP1 catalytic activity.
[217] 
In the central automodification domain, specific glutamate 
and lysine residues serve as acceptors of ADP-ribose moieties, thereby allowing the enzyme 
to poly(ADP-ribosyl)ate itself. Interestingly, this domain also comprises a BRCA1 
carboxy-terminal (BRCT) repeat motif, a protein–protein interaction domain that is found in 
other components of the DNA damage response pathway.
[218]
 The presence of this motif 
raises the possibility that unexplored protein–protein interactions involving this domain might 
also play an important part in PARP1 biology. Finally, the C-terminal catalytic domain 
sequentially transfers ADP-ribose subunits from NAD+ to protein acceptors, thereby forming 
pADPr25.
[219] 
BRCT domain is an abundant structural unit found in more than 100 proteins from all 
biological kingdoms. Structural, it is typically an αβα sandwich, characterized by four 
parallel β strands forming a central β sheet and flanked by three α-helices. Nearly all of the 




DNA and/or more directly in DNA replication and repair.
[220] 
 
Figure 4.1. a) Protein structure of PARP1 (BRCT domain is shown in the yellow box). b) Workflow of the 
microarray-assisted discovery of cell-permeable small molecule PPI inhibitors of PARP1 BRCT domains. c) 
Structure of compound 2-6 and Gossypol.  
 
BRCT domains most often function as protein binding domains; e.g. PARP1, binds X-ray 
repair cross-complementing protein 1(XRCC1) via its BRCT domain.
[221]
 The BRCT domain 
of PARP1 is required for efficient repair of DNA damage; however, there has been limited 
biological characterization of this domain, we here developed the high throughput platform 
by microarray technology for discovering the binding peptide for PARP1 BRCT domain, and 
then we set up the small molecule library screening platform by fluorescence 
polarization.
[222][223]
 To the best of our knowledge, this compound is the first small-molecule 
PPI inhibitor of PARP1 BRCT domain protein.
[224][225]
 We have carried out extensive 
validation assays to confirm that this compound directly binding with PARP1 BRCT domain 
by ITC and FP.   




4.3.1 Protein expression and purification 
His-tagged fusions of different human BRCT plasmid constructs (e.g. DNTT, POLM) were 
obtained by standard molecular cloning using Ligation Independent Cloning (LIC). All 
expression constructs were transformed into an E. coli. BL21(DE3) strain. Overnight cultures 
were diluted 1:100 in LB media supplemented with 100 μg/mL of ampicillin and grown at 
37 °C. At OD600 ~0.6-0.8, expression was induced by addition of 0.1 mM of IPTG 
(isopropyl- -D thiogalactopyranoside) and cultures were grown further at 18 °C overnight. 
The fusion proteins were soluble, expressed in high yields and the expression was verified by 
coommassie blue staining. After cell harvest and lysis (20 mM Tris-HCl, 150 mM NaCl, 0.2 
mM DTT, pH 7.4) by sonication (6X pulses of 15 s each at half maximal power, on ice), the 
solution was clarified by centrifugation at 10000 g, 30 min, 4 °C and loaded onto a column 
containing 200 μL of His-tagged resin (Amersham Biosciences) pre-equilibrated with a 
column buffer (20 mM Imidazole, 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.4). Following incubation for 20 min at 4 °C, the resin was washed 5 times 
with the column buffer and the fusion was eluted with elution buffer (200 mM Imidazole, 140 
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) or continuing to the 
next protein labeling step. GST-BRCA1-(BRCT)2 protein was similarly expressed, and 
purified by using standard GST purification protocols. For His-tagged proteins, continuing 
from the washing of resin with wash buffer, the resin was further washed twice with PBS 
buffer (pH 7.4). To the resulting resin, H2O, NaHCO3 (100 mM, pH 9.0) and Cy5-NHS ester 
were added. Following incubation on ice for 1 h, the unreacted dye was quenched with 3 M 
hydroxylamine (in 2.5 M NaOH) for further 30 min. PBS was used to wash the labeled-resins 
five times to remove the excess dye. The protein was finally eluted with elution buffer (200 
mM Imidazole, 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4). 




centrifugal filter device (cutoff: 3 KDa) and store at -20 °C with 20% glycerol added. To 
ensure successful protein labeling and purity, the labeled proteins were analyzed by 
separation on a 15% SDS-PAGE gel. 
BRCT domain protein Source Classification 
RFC1 H.sapiens DNA binding protein 
LIG3 H.sapiens DNA ligase 
LIG4 H.sapiens DNA ligase 
TERF2IP H.sapiens Cell cycle control protein 
PES1 H.sapiens Cell cycle control protein 
DNTT H.sapiens DNA polymerase 
POLM H.sapiens DNA polymerase 
PARP1 H.sapiens Ribosyltransferase 
Table 4.1 The classification and sources of eight different BRCT domain protein used in our 
study 
 
Figure 4.2 SDS-PAGE of eight BRCT domains protein labeled with Cy5 dye (in Red).(Lane1: 
RFC1; Lane2: PARP1; Lane3: LIG4; Lane4: LIG3; Lane5: PES1; Lane6: DNTT; Lane7: 
POLM; Lane8 : TERF2IP) 
 
4.3.2 Protein screening on the peptide microarray and analysis 
The labeled proteins were subsequently reconstituted in a final buffer volume of 80 μl 
PBS (pH 7.4) containing 1% bovine serum albumin (BSA). For GST-BRCA1-(BRCT)2 
protein, the purified protein was fluorescently labeled based on previously reported 
protocols.
[1]
 In a standard microarray experiment, the labeled protein (2 μM; 50 μL) was 
applied under coverslip to the array, as previously described.
[1]









experiment for Kd measurements, various concentrations of the protein (0.05 µM to 10 µM) 
were applied to different sub-arrays on the same slide, as previously described.
[1]
 Slides were 
scanned using an Array microarray scanner installed with the relevant filters (Cy3: λex/em = 
548/595 nm; Cy5: λex/em = 633/685 nm). Pro-Q™ staining was routinely carried out on 
spotted slides to ensure the consistency and quality of the slides.  
 
Figure 4.3 The 1000 peptides were spotted in duplicate (vertical), washed and treated with 
ProQ and imaged under Cy3 channel. The image shows that most spots (> 99 %) located on 
the array were spotted uniformly and consistently. 
 
Figure 4.4 Images of the 1000-member peptide library screened against 8 different 
Cy5-labeled BRCT domain protein, and one Cy3-labeled 14-3-3 sigma protein (internal 
control protein). 
Microarray data was extracted by using the instrument-installed software, as previously 
described.
[1]
 Values from duplicated points were background subtracted and averaged 
(Duplicated spots with a standard deviation > 0.2 were rejected). The dataset was presented 




Position specific scoring matrix analysis was performed using the software developed by 
Stephen Shaw (sshaw@nih.gov) and obtained and used with permission. Other data analysis 
was carried out with Microsoft Excel. All compounds were spotted onto the same slide where 
up to 3 identical subarrays were generated on the same platform, allowing consistent/uniform 







Figure 4.5. (a) Combined heat map of the 1000-member peptide library against eight 
Cy5-labeled BRCT domain proteins. Data were organized in the order of P+/-3 >P+/-2 > P+/-1. 




against any of the eight BRCT domain proteins. (b) Position specific scoring matrix (PSSM) 
representing averaged binding affinity across P+/-1, P+/-2 and P+/-3 positions for each amino 
acid. The height of each letter represents the weighted contribution of that residue to overall 
peptide binding. The side chains are colored according to their properties: 
hydrophobic/aromatic (black), acidic (red), basic (blue), polar (cyan), hydrophilic (green), 
and small (beige). 
 
Figure 4.6. Relative binding potency of eight BRCT domain protein across the six 
permutated positions (left to right: in the order of P-3, P-2, P-1, P+1, P+2 and P+3), as obtained 
from the analysis of top-50 hits from both the N- and C-terminal sub-libraries against each 
BRCT domain. Each bar represents the frequency of occurrence of a particular amino acid in 
the top 50 binders from each of the two sub-libraries.  
4.3.3 Synthesis the peptide hybrid libraries 
 










Table 4.1 120 small peptide hybrid library information summary 
 
Scheme 4.1 Synthesis scheme of the 120 peptide library. 
The synthesis was performed by using standard Fmoc Strategy combined with IRORI
TM
 
directed sorting technology, following previously published procedures.
[1] 
For the 120 library, 
Rink amide resin was used as the solid support. Standard HOBt/HBTU/DIPEA coupling 
method was used throughput the whole process. The HOBt/HBTU/DIPEA coupling method 
was proved to be the most ideal way to incorporate Fmoc-Ser[PO(OBzl)-OH]-OH. Each 
microreactor contains around 20 mg of rink amide resin and a unique RF tag for sorting 




Subsequently the Fmoc group was deprotected by treatment of 20% piperidine for 1 h at 
room temperature. Following removal of the piperidine, the resin was washed extensively 
with DMF and DCM. The microreactors were dried thoroughly in vacuo. After the first 
coupling of Fmoc- Lys(Biotin)-OH, any unreacted resin residue was capped with a solution 
of Ac2O (10 eq.), DIPEA (20 eq.) in DCM, and the reaction mixture was allowed to react for 
2 hr at room temperature, followed by extensive wash with DCM and DMF. Subsequently the 
resin was deprotected with 20% piperidine again and ready for next coupling cycle. Repeat 
the above cycle until the last amino acid, Fmoc-Ser[PO(OBzl)-OH]-OH was coupled. Repeat 
the cycle using HOBt/HBTU/DIPEA coupling method until the last amino acid was coupled. 
Biotin-GG was attached at the N-terminus of peptides for future microarray immobilization. 
Final capping was done with a solution of Ac2O (10 eq.), DIPEA (20 eq.) in DCM , and the 
reaction mixture was allowed to react for 2 h at room temperature, followed by extensive 
wash with DCM and DMF. 
4.3.4 Screen the second peptide hybrid library with protein and analysis 
To further identify the different position amino acid binding affinity, we designed the 
second library that concept termed “position modification combinatorial chemistry”. We 
retained the key pSer residue in the LRFpSVFF sequence, and systematically replaced the 
one position amino acid with 20 nature amino acid. It is means that we develop six sublibrary: 
LRFpSVFX, LRFpSVXF, LRFpSXFF, LRXpSVFF, LXFpSVFF, XRFpSVFF. After 
synthesis the 120 peptides library, immobilized on the avidin slides , incubation with 
Cy5-labeled PARP1 BRCT domain, further analysis was carried out by position specific 
sorting matrix, to determine that the binding motif of the PARP1 BRCT domain was 
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Figure 4.7 Microarray image for the 120 library screened with cy5-label PARP1 BRCT      
                 domain 
4.3.5 Synthesized the peptide contained the FITC tag 
We next investigated the Fluorescence Polarization (FP) assay for developing the small 
molecule inhibitor for PARP1 BRCT domain. The Fluorescence Polarization (FP) assay has 
been used successfully to identify small molecules as inhibitors of protein-protein interaction. 
[13]
 Polarization is a measure of the change in the molecular movement of a labeled species 
and is defined as the ratio of the difference between the vertical and horizontal components of 
the emitted light over the sum. Because polarization is a dimensionless value, it is 
independent of the emitted light or the concentration of the fluorophore. These features make 
the FP assay suitable for screening compound libraries in a high-throughput format to 





Scheme 4.2 Synthesis of the FITC tag labeled peptide. 
Briefly, the FITC labeled peptide was synthesized by solid phase chemistry, the peptide was 
immobilization on the Rink-amide resin, following previously published procedures,
[14] 
then 
coupling of the peptide sequence LRFpSVFF. FITC and a GG linker were introduced at the 
N-terminus of the peptide. After cleavage by tradition process and HPLC-purification, the 
final FITC-labeled peptide was characterized by IT-TOF MS 
4.3.6 Screened the 384 member library by FP assay 
Furthermore, an approximately 384 member library which contained nearly 150 Natural 
Product Screening library(Selleckchem, #L1400) was screened using the optimized FP assay 
in a 384-format.
[15] 
The Natural Product Screening library was preliminary screened at four 
concentration (1 µM, 10 µM, 100 µM, 1000 µM). FP values were measured after 15 min 
incubation at 25 °C in a thermostatted plate reader. The total fluorescence of the plate was 




concentrations, we choose the top ten compounds(N1A2, N1C9, N1E1, N1E6, N1F2, N1F7, 
N1H3, N1H9, 2-5 and 2-6) to further validation by concentration dependent FP competive 
assay. At the same time , we also process the thermal shift assay with the PARP1 BRCT 
domain and 384 library, the result is shown in the Supporting information. The summary 
table is shown in Figure 4.8), top five compound was listed in the table. All three binding 
experiments, e.g. FP, Tm determination and ITC, showed all Gossypol compounds were rela 
relatively potent binders of PARP1 BRCT, with Gossypol being the best binder of all (IC50 = 




Figure 4.8 Heatmap of the screening of the 384 library with FP assay. 
4.3.7 Validation of the chosen hit by FP assay and ITC 
The PARP1-BRCT domain FP assay was carried out in black 384-well microplates in a 
total volume of 20 µL in each well.
 
For each assay, three basic solutions were prepared. The 
reaction buffer used in the FP assay throughout this study contains 16 mM Na2HPO4, 4 mM 
NaH2PO4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, and 0.02% NaN3 at pH 7.3. Solution A 
contained a fluorescently labeled, the PARP1 BRCT domain binding peptide, FITC-GG- 
LRFpSVFF-CONH2 (purchased from GL Biochem), in the reaction buffer (solution with 2 
µM of the peptide probe). Solution B contained the PARP1 BRCT domain protein in the 
reaction buffer (solution with 60 µM of PARP1 BRCT domain). Solution C contained either a 




(with varied concentrations). Briefly, 17 µL of solution C and 2 µL of solution B were mixed 
and pre-incubated for 30 min at room temperature. Subsequently, 1 µL of solution A was 
added. After 60 min of incubation at room temperature, the polarization values were 
measured using an Infinite F200 microplate reader (Tecan, Austria) installed with 2 pairs of 
polarizers (λEx: 480 nm; λEm: 520 nm). The competitive effect was expressed as the 
percentage of control. IC50 values were determined from the model with nonlinear regression 
analysis, and summarized in Table S1.  
Thermal Shift Assay was determined using the Thermal Shift Assay Dye kit (Applied 
Biosystem, #4461146) following the manufacturer‟s guidelines. The PARP1 BRCT domain 
protein was added to a final concentration of 3 µM in the incubation buffer (contained 5 µL 
Protein Thermal Shift
TM
 Buffer, and 2.5 µL Protein Thermal Shift
TM
 dye). The final volume 
was 20 µL/well in an 384-well PCR plate. The temperature gradient was performed in the 
range of 30–80 °C, using a 7500 real-time PCR instrument from Applied Biosystems 
(Carlsbad, CA) with a standard ramp of 1% over the course of 60 min. The compound 
screening was performed at the 20 µM (in 5% DMSO) concentration of the test compounds. 
The detection of protein unfolding was performed with an excitation wavelength of 567 nm 
and an emission of 591 nm. 
ITC experiments were performed on an ITC200 calorimeter(GE Amersham) interfaced 
with a computer for data acquisition and analysis using Origin 7 software (Microcal Inc., 
Northampton, MA).
[2] 
The protein was extensively dialysed against 20 mM HEPES, 100 mM 
NaCl, pH 7.4 and the same buffer was used for reconstituting small molecule ligands. The 
experiments were carried out by titration of 20 mM protein in the sample cell with 300 mM 
of ligand in the titration syringe. The cell was thermostated at 25 
o
C and uniform mixing was 
ensured by continuous stirring of titration syringe at 600 rpm. Protein and ligand samples 
were degassed and pre-incubated to 25 
o




the calorimeter. All titration experiments were performed by addition of 2 µL titrant per 
injection, with 20-30 injections spaced at 200-second intervals. The first injection contained 
only 0.3 uL of titrant and the corresponding enthalpy data point was deleted before the data 
analysis. The binding isotherms were best-fit to a one-set binding-site model by Marquardt 
non-linear least-square analysis to obtain binding stoichiometry (N), association constant (Ka), 
change in enthalpy (ΔH), and change in entropy (ΔS) using Origin 7.0 software (Microcal 
Inc). The free energy (ΔG) and ΔS were calculated by the following equations, respectively: 
















































Table 4.1 Summary of FP, Thermal Shift and ITC Binding Data 
4.3.8 Cell Culture and Small Molecular Competition Studies 
The HeLa cell line was cultured in growth media (DMEM supplemented with 10% fetal 
bovine serum, and 100 IU/mL penicillin). Cells were maintained in a humidified atmosphere 




mM EDTA, 1% (vol/vol) NP-40, 2 mM DTT and 1 × Complete protease inhibitors cocktail 
(Roche, Germany) with the 1 × PhosSTOP phosphatase inhibitors cocktail (Roche, Germany). 
Lysates were incubated with His beads containing equal amounts of immobilized 
His-PARP1-BRCT overnight at 4 °C with rocking. The beads were washed three times with 







Figure 4.9 In-vitro inhibition assay for PARP1-Hsp70 interaction 
4.4 Conclusion 
In conclusion, we have firstly described the development and optimization of an FP assay 
that can be used to identify inhibitors of the PARP1 BRCT domain. The binding peptide 
sequence (LRFpSRFF) was firstly identified from the microarray technology with two 
libraries. The N-terminus-labeled FITC peptide bind with the PARP1 BRCT domain with a 
low micromolar Kd value. The competitive binding assay was used to demonstrate that 
PARP1 BRCT domain is indeed phophopeptide binding modules. The FP assay was 
miniaturized (20µl reaction) and adapted successfully to a high throughput format(384 
wells).Miniaturized assays not only enable the screening of larger libraries on identical 
footprints but also are cost-effective; therefore, the 384-well format was pursued for further 
optimization and screening. The Natural product screening libraries was screened under 
optimized assay conditions, and a small molecule inhibitor (compound 2-6 and Gossypol) of 







the PARP1 BRCT domain was identified. This hit currently is being validation in cell-base 
assays, the results of which will be reported in due course. 
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All chemicals were purchased from commercial vendors and used without further 
purification. Tetrahydrofuran (THF) was distilled over sodium benzophenone and used 
immediately. All reactions requiring anhydrous conditions were carried out under an argon or 
nitrogen atmosphere using oven-dried glassware. HPLC grade solvents are used for all other 
solvents. Reaction progress was monitored by TLC on precoated silica plates (Merck 60 F
254
, 
0.25 μm) and spots were visualized by UV, iodine or KMnO4 stain. Flash column 
chromatography was carried out using Merck 60 F
254
 0.040-0.063 μm silica gel. 1H and 13C 
NMR spectra were recorded on Bruker Avance ACF300 or AMX500 spectrometers. 
Chemical shifts are reported in parts per million relative to internal standard trimethylsilane 
(Si(CH3)4 = 0.00 ppm) or residual solvent peaks (CDCl3 = 7.26 ppm, MeOD = 3.31 ppm, 
DMSO = 2.50 ppm). UV-vis absorption/extinction and fluorescence spectra were measured 
by using a Shimadzu UV-vis spectrophotometer and a Perkin Elmer LS50 spectrofluorometer, 
respectively. The two-photon excitation fluorescence measurements were performed by using 
a Spectra Physics femtosecond Ti: sapphire oscillator (Tsunami) as the excitation source. The 
output laser pulses have a tunable center wavelength from 750 nm to 860 nm with pulse 
duration of 40 fs and a repetition rate of 76 MHz. The laser beam was focused onto the 
samples that were contained in a cuvette with path length of 1 cm. The emission from the 
samples was collected at 90° angle by a pair of lenses and an optical fiber that was connected 
to a monochromator (Acton, Spectra Pro 2300i) coupled with CCD (Princeton Instruments, 
Pixis 100B) system. A short pass filter with cut-off wavelength at 700 nm was placed before 
the spectrometer to minimize the scattering from the pump beam. All the measurements were 
performed at room temperature. 
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To a solution of 1 (100 mg, 0.32 mmol)
2 
and Boc-Homoserine(N3)-OH (100 mg, 0.4 mmol) 
in DCM (10 mL) was added EDC (153 mg, 0.8 mmol). The resulting mixture was stirred at 
room temperature overnight. The reaction was quenched by addition of water (20 mL) which 
was extracted with ethyl acetate (20 mL ×2). The collected organic layer washed with water 
(20 mL ×2), brine (20 mL ×2), dried over anhydrous Na2SO4 and concentrated in vacuo. The 
residue was purified by chromatography with hexane/ethyl acetate (4:1) to give the red 
powder (140 mg, 77% yield). 
1
H NMR (300 MHz, CDCl3): δ 8.29 (d, J = 9.0 Hz, 2H), 7.87 
(m, 4H), 6.80 (d, J = 9.0 Hz, 2H), 6.67 (s, 1H) 5.20 (s, 1H), 4.22 (s, 1H)3.54 (m, 5H),2.83 
(s,1H) 2.07 (m, 1H), 1.90 (m, 1H), 1.44 (s, 9H), 1.23 (t, J = 6.9 Hz, 3H);
 13
C NMR (75 MHz, 
CDCl3) δ 171.1, 156.3, 151.4, 147.5, 143.1, 126.1, 124.6, 122.6, 111.4, 48.8, 46.3, 45.4, 37.3, 
31.3, 28.2, 12.2; LC-MS(IT-TOF): calcd for [M+H]
+
 = 540.29, Found = 540.30. 
 
To a solution of 2 (140 mg, 0.26 mmol) in 10 mL DCM was added 3 mL TFA. The mixture 
was stirred at 0 
o
C for 1 h, then evaporated to dryness. Subsequently, 40 mL ethyl acetate was 
added, and the solution was washed with saturated aqueous NaHCO3 solution (20 mL ×3) and 
Brine (20 mL ×3), dried over anhydrous Na2SO4 and concentrated in vacuo. Further adding 
20 mL DCM, Boc-Phe-OH (80 mg, 0.3 mmol), and EDC (76 mg, 0.4 mmol), the resulting 
mixture was stirred at room temperature overnight. After quenched by water (20 mL), the 




with water (20 mL ×2), brine (20 mL ×2), dried over anhydrous Na2SO4 and concentrated in 
vacuo. The residue was purified by chromatography with hexane/ethyl acetate (4:1) to give 
the red powder (153 mg, 86% yield). 
1
H NMR (300 MHz, DMSO-d6): δ 8.33 (d, J = 9.0 Hz, 
2H), 8.16 (s, 1H), 8.13 (s, 1H), 7.93 (d, J = 9.0 Hz 2H), 7.82 (d, J = 9.0 Hz 2H), 7.27 (d, J = 
8.0 Hz, 2H), 7.19 (m, 1H), 7.06 (d, J = 8.0 Hz, 2H), 6.95 (d, J = 8.0 Hz, 2H), 4.32 (m, 1H), 
4.16 (m, 1H), 3.49 (m, 4H), 3.30 (m, 2H), 2.97 (m, 1H), 1.87 (m, 1H), 1.76 (m, 1H), 1.44 (s, 
9H), 1.23 (t, J = 6.9 Hz, 3H);
 13
C NMR (75 MHz, DMSO-d6) δ 172.2, 171.1, 156.3, 155.4, 
152.4, 147.5, 143.1, 138.3, 129.6, 128.4, 126.5, 125.3, 122.6, 111.4, 78.53, 56.28, 48.8, 47.3, 
45.4, 37.3, 36.9, 31.3, 28.2, 12.2; LC-MS(IT-TOF): calcd for [M+H]
+ 
= 687.30, Found = 
687.31. 
 
To a solution of 3 (153 mg, 0.22 mmol) in 10 mL DCM was added 3 mL TFA. The mixture 
was stirred at 0 
o
C for 1 h, then evaporated the solvent and TFA , added 40 mL ethyl acetate, 
washed with saturated aqueous NaHCO3 solution (20 mL ×3) and Brine (20 mL ×3), dried 
over anhydrous Na2SO4 and concentrated in vacuo. Further adding 20 mL DCM, 
5-phenylpentanoic acid (55 mg, 0.3 mmol), and EDC (76 mg, 0.4 mmol), the mixture was 
stirred at room temperature overnight. After being quenched by water (20 mL), the solution 
was extracted with ethyl acetate (40 mL ×2). The collected organic layer was washed with 
water (20 mL ×2), brine (20 mL ×2), dried over anhydrous Na2SO4 and concentrated in vacuo. 
The residue was purified by chromatography with hexane/ethyl acetate (1:1) to give the red 
powder (130 mg, 84% yield). 
1
H NMR (300 MHz, DMSO-d6): δ 8.34 (d, J = 9.0 Hz, 2H), 




2H), 7.24 (m, 5H), 7.13 (m, 5H), 6.95 (d, J = 8.0 Hz, 2H), 4.49 (m, 1H), 4.26 (m, 1H), 3.46 
(m, 4H), 3.30 (m, 2H), 2.99 (m, 1H), 2.87 (s, 1H), 2.83 (m, 1H), 2.76 (s, 1H), 2.30 (s, 1H), 
2.17 (s, 1H), 1.89 (m, 1H), 1.78 (m, 1H), 1.36 (m, 5H), 1.27 (m, 2H), 1.23 (t, J = 6.9 Hz, 3H);
 
13
C NMR (75 MHz, DMSO-d6) δ 172.2, 171.6, 171.1, 156.3, 152.4, 147.5, 142.1, 129.6, 
128.6, 128.4, 128.3, 126.5, 125.9, 125.4, 122.8, 111.8, 54.28, 50.1, 48.8, 47.3, 45.4, 37.3, 
35.9, 31.3, 30.4, 29.2, 25.5, 22.5, 12.2; LC-MS(IT-TOF): calcd for [M+H]
+
 = 747.37, Found 
= 747.38. 
 
Compound 5 was synthesized based on the same procedure as 4 by using 
2-((1,1'-biphenyl)-4-yl)acetic acid to afford red powder (137 mg, 85% yield). 
1
H NMR (300 
MHz, DMSO-d6): δ 8.43 (d, J = 9.0 Hz, 2H), 8.34 (d, J = 9.0 Hz, 2H), 8.25 (d, J = 9.0 Hz, 
2H), 8.06 (m, 1H), 7.93 (d, J = 9.0 Hz 2H), 7.86 (d, J = 9.0 Hz 2H), 7.58 (d, J = 9.0 Hz, 2H), 
7.48 (d, J = 9.0 Hz, 2H), 7.43(d, J = 9.0 Hz, 2H), 7.36 (m, 1H), 7.24 (m, 4H), 7.21 (m, 3H), 
6.95 (d, J = 8.0 Hz, 2H), 4.55 (m, 1H), 4.27 (m, 1H), 3.46 (m, 4H), 3.30 (m, 2H), 2.99 (m, 
1H), 2.87 (s, 1H), 2.83 (m, 1H), 2.76 (s, 1H), 2.30 (s, 1H), 2.17 (s, 1H), 1.89 (m, 1H), 1.78 (m, 
1H), 1.24 (t, J = 6.9 Hz, 3H);
 13
C NMR (75 MHz, DMSO-d6) δ 171.6, 171.4, 170.3, 156.3, 
152.4, 147.5, 142.1, 140.3, 138.6, 138.1, 135.8, 129.8, 129.6, 129.2, 128.6, 127.4, 126.5, 
125.9, 122.8, 111.8, 55.28, 50.1, 48.8, 47.3, 45.4, 42.4, 37.3, 35.9, 31.3, 12.2; 
LC-MS(IT-TOF): calcd for [M+H]
+





Compound 4 (100 mg, 13 mmol) and the corresponding alkyne-containing dye DL-1 (67 mg, 
14 mmol) were suspended in a mixture of DMSO/acetonitrile (2:1) (9 mL). To the suspension 
was added CuI (25 mg, 14 mmol) and DIEA (50 µL). The resulting mixture was stirred at 
room temperature for 48 h. Then the product was directly purified by preparative HPLC with 
elution gradients using acetonitrile (0.1% TFA) and water (0.1% TFA) to give the final 
product 13 mg. 
1
H NMR (300 MHz, DMSO-d6): δ 8.33 (m, 3H), 8.15 (m, 3H), 7.99 (m, 2H), 
7.84 (d, 3H), 7.76 (m, 2H), 7.57 (d, 3H), 7.25(m, 12H), 7.05 (m, 3H), 6.9 (m, 5H), 5.6 (m, 
2H), 4.51 (m, 1H), 4.35 (m, 2H), 4.20 (m, 2H), 3.46 (m, 11H), 3.27 (m, 2H), 2.99 (m, 1H), 
2.87 (s, 1H), 2.83 (m,2H), 2.18 (m, 1H), 2.08 (m, 3H), 1.40 (m, 4H), 1.08 (m, 16H);
 13
C 
NMR (75 MHz, DMSO-d6) δ 173.6, 172.16, 171.3, 164.67, 156.3, 151.4, 147.5, 142.3, 
138.25, 135.8, 128.54, 128.37, 126.5, 125.24, 122.79, 111.8, 110.05, 60.35, 54.32, 50.56,  
46.5, 45.21, 37.3, 35.3, 35.18, 32.64, 30.69, 25.07, 12.4; LC-MS(IT-TOF): calcd for [M+H]
+
 





ZK-2 was synthesized used the same procedure as ZK-1 by using compound 5 to afford the 
final product 10 mg. 
1
H NMR (300 MHz, DMSO-d6): δ 8.43 (m, 2H), 8.34 (m, 2H), 8.15 (m, 
3H), 8.05 (m, 2H), 7.81 (d, 5H), 7.47 (m, 10H), 7.25 (m, 10H), 6.90 (m, 6H), 5.60 (m, 2H), 
4.51 (m, 1H), 4.35 (m, 2H), 4.20 (m, 2H), 3.46 (m, 7H), 3.27 (m, 2H), 2.99 (m, 1H), 2.87 (s, 
1H), 2.83 (m,2H), 2.49 (m, 4H), 1.08 (m, 16H) ;
 13
C NMR (75 MHz, DMSO-d6) δ 172.9, 
171.2, 165.5, 164.6, 156.7, 154.7, 151.9, 147.3, 143.1, 142.3, 138.25, 137.9, 135.8, 129.2, 
129.4, 128.54, 128.37, 126.8, 126.5, 125.28, 122.79, 111.8, 111.6, 66.35, 65.21, 63.77, 54.32, 
54.32, 45.14, 35.18, 34.13, 29.51, 12.4; LC-MS(IT-TOF): calcd for [M+H]
+
 = 1161.64, 
Found = 1161.65. 
5.2.2 Cell culture and cell imaging 
HepG2 cells were seeded in glass-bottom dishes (Mattek) and grown till 70~80% confluency. 
Subsequently, the cells were incubated with ZK-1 or ZK-2 (2 µM prepared in fresh media) 
for 2 h, then further incubated with 0.25 µg/mL of the lysosomal tracker (LysoTracker
®
 Red 
DND-99). Cells were next washed with PBS three times, then imaged with the Leica TCS 
SP5X Confocal Microscope System equipped with Leica HCX PL APO 63x/1.20 W COPP 
CS, 405 nm Diode laser, White laser (470 nm to 670 nm, with 1 nm increments, with 8 
channels AOT for simultaneous control of 8 laser lines, each excitation wavelength provides 
1.5 mV), and Ti-Sappire laser (~4 W at 800 nm) with PMT detector ranging from 420 nm to 
700 nm for one-photon excited fluorescence. All images were processed with Leica 
Application Suite Advanced Fluorescence 
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H-NMR (500 MHz, DMSO-d6) 8.49 (t, J = 5.72 Hz, 1H), 8.35 (d, J = 4.98 Hz, 1H), 7.12(m, 
4H), 7.09(m, 4H), 4.52 (d, J = 4.98 Hz, 1H), 4.22 (t, J = 4.38 Hz, 1H), 3.97 (m, 2H), 2.28 (s, 
6H). ESI: m/z [M+Na]
+ 
calced: 443.1342, found: 443.1347. 
 
1
H-NMR (500 MHz, DMSO-d6) 8.47 (t, J = 5.72 Hz, 1H), 8.33(d, J = 4.98 Hz, 1H), 7.13(m, 
5H), 7.08(m, 4H), 4.51 (t, J = 4.98 Hz, 2H), 4.27 (t, J = 4.38 Hz, 2H), 3.97 (m, 2H), 2.28 (s, 
3H). ESI: m/z [M+Na]
+ 




H-NMR (500 MHz, DMSO-d6) δ 8.85 (d, J = 4.77 Hz, 1H), 8.52 (t, J = 5.77 Hz, 1H), 8.07 
(d, J = 7.98 Hz, 1H), 7.82 (t, J = 4.76 Hz, 1H), 7.63 (t, J = 4.57 Hz, 1H), 7.48 (t, J = 5.77 Hz, 
1H), 7.13 (m, 5H), 6.79 (M, 2H), 5.92 (d, J = 6.38 Hz, 1H), 5.37 (d, J = 6.38 Hz, 1H), 4.57 
(m, 1H), 3.87-4.03 (m, 2H), 2.31 (s, 3H). ESI: m/z [M+Na]
+








J = 7.96 Hz, 1H), 7.73 (t, J = 4.76 Hz, 1H), 7.13 (m, 4H), 4.65 (s, 1H), 4.27 (m,3H), 2.27 (s, 
3H). ESI: m/z [M+Na]
+
calced: 478.0786, found: 478.0790. 
 
1
H-NMR (500 MHz, DMSO-d6) δ 8.49 (d, J = 4.45 Hz, 1H), 8.21 (t, J = 5.13 Hz, 1H), 7.43 
(d, J = 4.76 Hz, 2H), 7.35 (d, J = 4.57 Hz, 2H), 7.25 (t, J = 5.77 Hz, 1H), 7.15 (m, 4H), 6.46 
(d, J = 6.32 Hz, 1H), 6.34 (d, J = 6.32 Hz, 1H), 4.51 (m, 1H), 4.22 (m, 2H), 4.05 (m, 2H), 
2.22 (s, 3H). ESI: m/z [M+Na]
+
calced: 455.1342, found: 455.1338. 
 
1
H-NMR (500 MHz, DMSO-d6) 8.48 (t, J = 5.72 Hz, 1H), 8.32 (d, J = 4.98 Hz, 1H), 7.11(m, 
4H), 7.03(m, 4H), 4.62 (d, J = 4.98 Hz, 1H), 4.42 (t, J = 4.38 Hz, 1H), 3.91 (m, 2H), 2.34 (s, 
3H), 2.31(s, 3H). ESI: m/z [M+Na]
+ 
calced: 459.1890, found: 459.1889. 
 
1
H-NMR (500 MHz, DMSO-d6) 8.46 (t, J = 5.72 Hz, 1H), 8.31(d, J = 4.98 Hz, 1H), 7.14(m, 
5H), 7.02(m, 4H), 4.41 (T, J = 4.98 Hz, 2H), 4.37 (t, J = 4.38 Hz, 2H), 3.91 (m, 2H), 2.22 (s, 
3H). ESI: m/z [M+Na]
+ 








(d, J = 7.98 Hz, 1H), 7.56 (t, J = 4.76 Hz, 1H), 7.17 (t, J = 4.57 Hz, 1H), 7.58 (t, J = 5.77 Hz, 
1H), 7.14 (m, 5H), 6.77 (M, 2H), 5.95 (d, J = 6.38 Hz, 1H), 5.47 (d, J = 6.31 Hz, 1H), 4.55 
(m, 1H), 3.81-4.02 (m, 2H), 2.33 (s, 3H). ESI: m/z [M+Na]
+




H-NMR (500 MHz, DMSO-d6) δ 8.71 (d, J = 4.71 Hz, 1H), 8.49 (t, J = 5.73 Hz, 1H), 8.41(d, 
J = 7.96 Hz, 1H), 7.72 (t, J = 4.76 Hz, 1H), 7.13 (m, 4H), 4.67 (s, 1H), 4.17 (m,3H), 2.29 (s, 
3H). ESI: m/z [M+Na]
+
calced: 494.1375, found: 494.1360. 
 
1
H-NMR (500 MHz, DMSO-d6) δ 8.51 (d, J = 4.45 Hz, 1H), 8.24 (t, J = 5.13 Hz, 1H), 7.40 
(d, J = 4.76 Hz, 2H), 7.34 (d, J = 4.57 Hz, 2H), 7.27 (t, J = 5.77 Hz, 1H), 7.23 (m, 4H), 6.45 
(d, J = 6.32 Hz, 1H), 6.32 (d, J = 6.32 Hz, 1H), 4.51 (m, 1H), 4.22 (m, 2H), 4.13 (m, 2H), 
2.35 (s, 3H). ESI: m/z [M+H]
+
calced: 449.1806, found: 449.1823. 
 
1
H-NMR (500 MHz, DMSO-d6) 8.34 (d, J = 5.72 Hz, 1H), 8.30(d, J = 4.98 Hz, 1H), 7.51 (d, 
J = 5.12 Hz, 1H), 7.22(m, 5H), 7.15(m, 5H), 4.43 (t, J = 4.98 Hz, 2H), 4.03 (t, J = 4.38 Hz, 
2H), 1.68 (m, 4H), 1.03(s, 3H). ESI: m/z [M+Na]
+ 






H-NMR (500 MHz, DMSO-d6) 8.35 (d, J = 5.73 Hz, 1H), 8.31(d, J = 4.97 Hz, 1H), 7.53 (d, 
J = 5.11 Hz, 1H), 7.22(m, 10H), 7.15(m, 5H), 4.63 (t, J = 4.91 Hz, 2H), 4.40 (t, J = 4.13 Hz, 
1H), 4.23 (t, J = 4.38 Hz, 2H), 1.65 (m, 4H). ESI: m/z [M+Na]
+ 




H-NMR (500 MHz, DMSO-d6) 8.37 (d, J = 5.13 Hz, 1H), 8.22 (d, J = 4.57 Hz, 1H), 7.33 (d, 
J = 4.11 Hz, 1H), 7.22(s, 2H), 7.15(m, 5H), 4.61 (t, J = 4.91 Hz, 2H), 4.42 (t, J = 4.13 Hz, 
2H), 4.23 (t, J = 4.31 Hz, 2H), 1.65 (s, 9H). ESI: m/z [M+Na]
+ 




H-NMR (500 MHz, DMSO-d6) 8.41 (d, J = 5.43 Hz, 1H), 8.36(d, J = 4.97 Hz, 1H), 7.23 (d, 
J = 5.11 Hz, 1H), 7.22(m, 4H), 7.14(m, 5H), 4.63 (t, J = 4.91 Hz, 2H), 4.40 (t, J = 4.13 Hz, 









H-NMR (500 MHz, DMSO-d6) 8.35 (d, J = 5.71 Hz, 1H), 8.36(d, J = 4.98 Hz, 1H), 7.54 (d, 
J = 5.12 Hz, 1H), 7.25(m, 5H), 7.17(m, 5H), 4.41 (t, J = 4.98 Hz, 2H), 4.02 (t, J = 4.31 Hz, 
2H),3.05(m, 4H) 1.68 (m, 4H), ESI: m/z [M+Na]
+ 
calced: 567.1972, found: 567.1989. 
 
1
H-NMR (500 MHz, DMSO-d6) 8.36 (d, J = 5.11 Hz, 1H), 8.35(d, J = 4.98 Hz, 1H), 7.53 (d, 
J = 5.12 Hz, 1H), 7.26(m, 5H), 7.15(m, 5H), 4.43 (t, J = 4.91 Hz, 2H), 4.01 (t, J = 4.31 Hz, 
2H),3.01(m, 4H) 1.67 (m, 4H), ESI: m/z [M+Na]
+ 
calced: 487.2326, found: 487.2328. 
5.3.2  Docking experiments
 
The BRCA1-(BRCT)2 domain structure was obtained from PDB (PDB ID: 3K0K). 
Explicit hydrogen atoms were added and all water molecules were then deleted. The peptide 
ligand was removed and the protein structure was processed using AutoDock Tools. 
Compound 15 was prepared for docking using AutoDock Tools to assign AD4 atom types, 
calculate Gasteiger charges, and set all rotatable bonds as active torsions. The ligand was 
docked into the protein using AutoDock Vina (version 1.11; Scripps Research Institute). The 
grid box was centered on the ligand in the active site of original crystal structure. The 
macromolecule molecular surface and secondary structure were displayed by PyMol (version 





Figure 5.1 Molecular docking of Compound 15 in the phosphopeptide binding pocket of 
BRCA1 BRCT domain. Protein is shown in green. And superimposition of Compound15 
bound to BRCA1 BRCT domain (surface representation) 
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LRFpSVFF 0.86 ± 0.12 
LRFSVFF N.A. 
 
Figure 5.2 a) concentration dependent of FITC-LRFpSVFF-CONH2 binding with PARP1 
protein. b) FP data for different version peptide against the PARP1 protein. 































Figure 5.3 a) concentration dependent of FITC-LRFpSVFF-CONH2 binding with BRCA1 
protein. 
5.4.3  IC50 result for Gossypol against the FITC-BRCA1 pS peptide. 



























5.4.4 Highlight some choosed small molecule inhibitor from the thermal shift assay 
screening against the PARP1 BRCT domain 
 
 





















































































Figure 5.4 Some compounds FP results 




        Gossypol                     2-6 
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The aim of my research has set up a platform for microarray assistant small molecular 
inhibitor discovery. This platform can be used to (1) high-capacity, high-throughput screening 
tool for discovery the small molecule inhibitor for the protein-protein interaction; (2) high- 
throughput identification of inhibitors targeting enzymes and profiling cellular events; (3) 
study the behavior of inhibitory binders on non-enzymatic protein and (4) profile enzyme 
activity and drug development.  
In Chapter 2, by using a small molecule microarray as a high-throughput screening 
platform, we have successfully discovered two potent inhibitors N02 and N17 of 
cathepsin L which were converted strategically into the corresponding two-photon small 
molecule imaging probes (ZK-1 and ZK-2). N02 and N17 were cell-permeable and could 
detect endogenous cysteinyl cathepsin activies from cell lysates or live mammalian cells 
of HepG2 cancer cells.The IC50 for these two inhibitor is 16nM and 20nm. Compared with 
the previous research, the inhibitors we chose have lower IC50 than that of the literature 
values reported. After converting the inhibitor to two-photon small molecule probes 
(ZK-1 and ZK-2), ZK-1 and ZK-2 can be cleaved by the Cathepsin L in-vivo and change 
the FRET pair, following the fluroscence can be detected by the microscopy machine. It 
should be noted that the probes could penetrate into the cell in two hours and the 
fluroscence would be detected after 2 hours, these may be improved by modifying the dye 
molecule to the small version to make better cleavage effect of Cathepsin L. Future 
extension of this approach will focus on developing imaging probes that can distinguish 
different cysteinyl cathepsins.    
In Chapter 3, a peptide-based library has been developed that enables high-throughput 
identification of BRCT domain of BRCA1 protein in cellular assay. In this experiment, we 
finally found that the small molecule N19 displays high specific binding to the BRCT domain 




for BRCA1 protein was 3 nM. Our work shows that based on the microarray screening of 100 
compounds library, N19 is the best inhibitor for BRCA1 protein. We find that N19 can induce 
apoptosis for HeLa cancer cell line. This shows that the N19 is a likely drug-candidate for 
further medicine application. It is acknowledged that this study did the preliminary analysis 
of the BRCA1 with the designed 100 phosphorserine compounds library, it is limited in that 
the phosphorserine compounds would be dephosphorized during the cell assay, because some 
enzymes in the cell will dephosphorized the phosphor compounds. In the next research, we 
should choose the phosphorserine mimic compound, which is stable during the cell assay, and 
even design the further inhibitor version which is stable and best inhibition effect. Future 
work is needed to identify the mechanism of the inhibitor N19 involved in the 
BRCA1-protein interaction. 
In Chapter 4, we discovered that the fragment based small molecular microarray could be 
used to identify inhibitory binders targeting PARP1 protein family. This work demonstrated 
that SMM constructed with a recognition sequence that targets an entire family of 
phosphoserine/phosphothreonine-binding proteins, and it can be used to effectively identify 
small molecular inhibitory binders that disrupt protein/ligand binding. Through the 
development of inhibitors targeting PARP1/ligand interactions, it shows that PARP1 protein 
is important mediator of survival signals. This suggests that the PARP1 is essential in 
mammalian cells. This work may have practical applications in treatment of diseases 
involving dis-regulated apoptosis and could also aid in the dissection of the function of 
PARP1 in other cellular processes. Although the small molecular compounds identified and 
synthesized in this work have greatly improved the non-peptide based inhibitor discovery, 
they are relatively labile in inner cellular level because of the incorporation of phosphoserine. 
An improved version is that we design the non-hydrolysable mimic. And this will improve 




chemical biology approach can be directly applied to any modular protein domain that 
recognizes phosphoserine, phosphothreonine or phosphotyrosine residues including FHA 
domains, WW domains, and SH2 domains. Thus, the SMM coupled with fragment-based 
screening described here, constitutes a class of reagents with significant general utility for the 
molecular dissection of signaling pathways within cells. 
A significant part of my work focused on the application of microarray for high-throughput 
identification of inhibitors targeting protein domain, which is a part of protein sequence and 
structure that can evolve, function, and exist independently of the rest of the protein chain in 
human body.  
There are several interesting directions for future work in the areas of research presented in 
this thesis: 
One possible avenue for future work is the development the small molecule drug for cancer 
cell. The target proteins such as BRCA1, PARP1 are very active in the human cancer cell. It 
may be possible to extend the small molecule inhibitor to further research on the cancer cell.   
Another extension of the work would be applied in wider biomarker discovery applications, 
using the precious and often limited sample. The probes designed for cathepsins and caspases 
have different activity between cancer cell line and normal cell line. So these can be used as 
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Appendix. Structure and MS Information of G1-50 Compounds for Chapter 3 
 
 





































































































































































































































































































Appendix. Thermal Shifts Graphs of G1-50 Compounds (and Blank) for Chapter 3 
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Appendix. Thermal Shifts Graphs of Compounds for Chapter 3 
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Appendix Thermal shift assay result for small molecule against the PARP1 BRCT 
domain for Chapter 4 



























Appendix Thermal shift assay and FP assay results for 384 compounds for Chapter 4 
 
384 position Name Kd(µM) Tm(°C) 















A7 Aesculin (Esculin) N.D. 43.88 
A8 Astragaloside A N.D. 43.81 
A9 Amygdalin N.D. 43.26 
A10 Andrographolide N.D. 43.42 
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A11 Apigenin N.D. 43.22 
A12 14-3-3 1-1 N.D. 43.52 
A13 10-Hydroxycamptothecin N.D. 43.67 





A16 Shikimic acid (Shikimate) N.D. 43.68 
A17 Silibinin (Silybin) 27.9 44.12 
A18 Silymarin (Silybin B) N.D. 43.29 





A21 Synephrine (Oxedrine) N.D. 43.53 
A22 Tangeretin (Tangeritin) N.D. 43.47 
A23 Tanshinone I N.D. 43.29 
A24 14-3-3 2-3 N.D. 43.88 
B1 Arbutin (Uva, p-Arbutin) N.D. 43.77 
B2 Naringenin N.D. 43.21 
B3 Artesunate N.D. 43.42 





B6 Baicalein N.D. 43.76 
B7 Baicalin N.D. 43.24 
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B8 Bergenin (Cuscutin) N.D. 43.66 
B9 Berberine Hydrochloride N.D. 43.43 
B10 β-Sitosterol N.D. 43.64 
B11 Bilobalide N.D. 43.48 

















B17 Troxerutin N.D. 43.27 
B18 Ursolic acid (Malol) N.D. 43.27 














B24 14-3-3 2-4 N.D. 43.66 
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C1 Caffeic acid N.D. 43.57 
C2 Chlorogenic acid N.D. 43.59 
C3 Chrysin N.D. 43.49 



















C11 Diosgenin N.D. 43.79 

















C17 Hordenine N.D. 43.59 













C22 Polydatin (Piceid) N.D. 43.72 
C23 Quercetin (Sophoretin) N.D. 43.36 
C24 14-3-3 2-5 15.8 44.06 





D3 Ecdysone N.D. 43.62 
D4 Emodin N.D. 43.69 
D5 Enoxolone (Glycyrrhetin) N.D. 43.81 
D6 Ergosterol N.D. 43.23 





D9 Fumalic acid (Ferulic acid) N.D. 43.41 
D10 Guanosine N.D. 43.62 
D11 Glycyrrhizic acid N.D. 43.45 
 187 
 
D12 14-3-3 1-4 N.D. 43.74 
D13 Sesamin (Fagarol) N.D. 43.6 





D16 Salidroside (Rhodioloside) N.D. 43.78 
D17 Palmatine chloride N.D. 43.64 





D20 Rhein (Monorhein) N.D. 43.85 





D23 Tetrandrine (Fanchinine) N.D. 43.47 
D24 14-3-3 2-6 5.7 44.61 
E1 Gossypol 0.54 45.11 
E2 Gramine N.D. 43.61 
E3 Empty N.D. 43.29 
E4 Gynostemma Extract N.D. 43.59 
E5 Hesperetin N.D. 43.26 
E6 Hesperidin 23.2 44.11 
E7 Honokiol N.D. 43.74 




E9 Icariin N.D. 43.78 
E10 Indole-3-carbinol N.D. 43.82 
E11 Kaempferol N.D. 43.62 
E12 14-3-3 1-5 N.D. 43.37 
E13 D-Mannitol (Osmitrol) N.D. 43.85 
E14 Isoliquiritigenin N.D. 43.89 





E17 Curcumol N.D. 43.52 
E18 Neohesperidin N.D. 43.68 
E19 Xanthone (Genicide) N.D. 43.41 






















F3 Limonin N.D. 43.71 
F4 Luteolin N.D. 43.21 
F5 Magnolol N.D. 43.85 
F6 Matrine ((+)-Matrine) N.D. 43.71 
F7 Methyl-Hesperidin 25.7 43.53 
F8 
Monensin sodium salt 
(Coban) 
N.D. 43.58 
F9 Morin hydrate (Aurantica) N.D. 43.35 
F10 Myricetin (Cannabiscetin) N.D. 43.25 
F11 Myricitrin (Myricitrine) N.D. 43.72 
F12 14-3-3 1-6 N.D. 43.59 
F13 Hypoxanthine N.D. 43.48 
F14 Rotundine N.D. 43.75 
F15 Inosine N.D. 43.75 
F16 BRCA1 hit 2 N.D. 43.31 
F17 BRCA1 hit 3 N.D. 43.67 
F18 BRCA1 hit 4 N.D. 43.62 
F19 BRCA1 hit 5 N.D. 43.56 
F20 BRCA1 hit 6 N.D. 43.31 
F21 BRCA1 hit 7 N.D. 43.66 
F22 BRCA1 hit 8 N.D. 43.24 
F23 BRCA1 hit 9 N.D. 43.29 
F24 BRCA1 hit 10 N.D. 43.45 
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G1 Nalidixic acid (NegGram) N.D. 43.84 
G2 Naringin (Naringoside) N.D. 43.87 
























G12 14-3-3 2-1 N.D. 43.39 
G13 BRCA1 hit 11 N.D. 43.25 
G14 BRCA1 hit 12 N.D. 43.63 
G15 BRCA1 hit 13 N.D. 43.87 
G16 BRCA1 hit 14 N.D. 43.77 
G17 BRCA1 hit 15 N.D. 43.58 
G18 BRCA1 hit 16 N.D. 43.89 
G19 Dasatinib N.D. 43.84 
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G20 VX680 N.D. 43.44 
G21 SP600125 N.D. 43.23 
G22 Imatinib N.D. 43.73 
G23 Sorafeinib N.D. 43.23 
G24 Purvalanol B N.D. 43.69 




























H11 Cyclocytidine HCl N.D. 43.46 
H12 14-3-3 2-2 N.D. 43.83 
H13 PD0325901 N.D. 43.62 
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H14 Sunitinib N.D. 43.81 
H15 Staurosphorine N.D. 43.26 
H16 Gefeitinb N.D. 43.72 
H17 SB-203580 N.D. 43.86 
H18 THL N.D. 43.39 
H19 K11777 N.D. 43.51 
H20 JQ1 N.D. 43.73 
H21 THL-A1 N.D. 43.64 
H22 THL-A2 N.D. 43.26 
H23 THL-A3 N.D. 43.36 
H24 THL-A4 N.D. 43.81 
I1 THL-A5 N.D. 43.37 
I2 THL-A6 N.D. 43.29 
I3 THL-A7 N.D. 43.43 
I4 THL-A8 N.D. 43.49 
I5 THL-A9 N.D. 43.45 
I6 THL-A10 N.D. 43.52 
I7 THL-A11 N.D. 43.62 
I8 THL-A12 N.D. 43.67 
I9 THL-A13 N.D. 43.24 
I10 THL-A14 N.D. 43.42 
I11 THL-A15 N.D. 43.62 
I12 THL-A16 N.D. 43.36 
I13 THL-A17 N.D. 43.66 
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I14 THL-A18 N.D. 43.29 
I15 THL-A19 N.D. 43.33 
I16 THL-A20 N.D. 43.31 
I17 THL-A21 N.D. 43.85 
I18 THL N.D. 43.53 
I19 THL-1 N.D. 43.89 
I20 THL-2 N.D. 43.49 
I21 THL-3 N.D. 43.88 
I22 THL-4 N.D. 43.47 
I23 THL-5 N.D. 43.84 
I24 THL-6 N.D. 43.39 
J1 THL-7 N.D. 43.74 
J2 THL-8 N.D. 43.37 
J3 THL-9 N.D. 43.28 
J4 THL-10 N.D. 43.27 
J5 THL-11 N.D. 43.22 
J6 THL-12 N.D. 43.81 
J7 THL-13 N.D. 43.34 
J8 THL-14 N.D. 43.46 
J9 THL-15 N.D. 43.51 
J10 THL-16 N.D. 43.65 
J11 THL-17 N.D. 43.62 
J12 THL-18 N.D. 43.35 
J13 THL-19 N.D. 43.58 
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J14 THL-20 N.D. 43.38 
J15 THL-21 N.D. 43.84 
J16 THL-22 N.D. 43.58 
J17 THL-23 N.D. 43.83 
J18 THL-24 N.D. 43.68 
J19 ibt-acetic-acid N.D. 43.57 
J20 ibt-propionic acid N.D. 43.77 
J21 ibt-butyric acid N.D. 43.53 
J22 ibt-isobutyric acid N.D. 43.37 
J23 ibt-dimethyl acid N.D. 43.26 
J24 ibt-ethyloxyl acid N.D. 43.75 
K1 ibt-gly-acid N.D. 43.55 
K2 ibt-cyclohexane acid N.D. 43.28 
K3 ibt-norbornane acid N.D. 43.29 
K4 ibt-cyclopentyl acid N.D. 43.54 
K5 ibt-4-ome acid N.D. 43.84 
K6 jq1-acetic-acid N.D. 43.39 
K7 jq1-propionic acid N.D. 43.86 
K8 jq1-butyric acid N.D. 43.38 
K9 jq1-isobutyric acid N.D. 43.43 
K10 jq1-dimethyl acid N.D. 43.43 
K11 jq1-ethyloxyl acid N.D. 43.71 
K12 jq1-gly-acid N.D. 43.79 
K13 jq1-cyclohexane acid N.D. 43.56 
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K14 jq1-norbornane acid N.D. 43.43 
K15 jq1-cyclopentyl acid N.D. 43.27 
K16 jq1-4-ome acid N.D. 43.41 
K17 nap-acetic-acid N.D. 43.69 
K18 nap-propionic acid N.D. 43.29 
K19 nap-butyric acid N.D. 43.55 
K20 nap-isobutyric acid N.D. 43.84 
K21 nap-dimethyl acid N.D. 43.69 
K22 nap-ethyloxyl acid N.D. 43.44 
K23 nap-gly-acid N.D. 43.72 
K24 nap-cyclohexane acid N.D. 43.65 
L1 nap-norbornane acid N.D. 43.48 
L2 nap-cyclopentyl acid N.D. 43.36 
L3 nap-4-ome acid N.D. 43.58 
L4 ome-acetic-acid N.D. 43.83 
L5 ome-propionic acid N.D. 43.22 
L6 ome-butyric acid N.D. 43.84 
L7 ome-isobutyric acid N.D. 43.64 
L8 ome-dimethyl acid N.D. 43.57 
L9 ome-ethyloxyl acid N.D. 43.36 
L10 ome-gly-acid N.D. 43.38 
L11 ome-cyclohexane acid N.D. 43.48 
L12 ome-norbornane acid N.D. 43.59 
L13 ome-cyclopentyl acid N.D. 43.57 
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L14 ome-4-ome acid N.D. 43.39 
L15 cn-4-ome acid N.D. 43.45 
L16 cn-acetic-acid N.D. 43.89 
L17 cn-propionic acid N.D. 43.42 
L18 cn-butyric acid N.D. 43.57 
L19 cn-isobutyric acid N.D. 43.25 
L20 cn-dimethyl acid N.D. 43.68 
L21 cn-ethyloxyl acid N.D. 43.64 
L22 cn-gly-acid N.D. 43.43 
L23 cn-cyclohexane acid N.D. 43.38 
L24 cn-norbornane acid N.D. 43.65 
M1 cn-cyclopentyl acid N.D. 43.59 
M2 cn-4-ome acid N.D. 43.62 
M3 ch-4-ome acid N.D. 43.88 
M4 ch-acetic-acid N.D. 43.63 
M5 ch-propionic acid N.D. 43.86 
M6 ch-butyric acid N.D. 43.54 
M7 ch-isobutyric acid N.D. 43.38 
M8 ch-dimethyl acid N.D. 43.65 
M9 ch-ethyloxyl acid N.D. 43.61 
M10 ch-gly-acid N.D. 43.89 
M11 ch-cyclohexane acid N.D. 43.59 
M12 ch-norbornane acid N.D. 43.34 
M13 ch-cyclopentyl acid N.D. 43.82 
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M14 ch-4-ome acid N.D. 43.73 
M15 cp-acetic-acid N.D. 43.38 
M16 cp-propionic acid N.D. 43.73 
M17 cp-butyric acid N.D. 43.47 
M18 cp-isobutyric acid N.D. 43.54 
M19 cp-dimethyl acid N.D. 43.53 
M20 cp-ethyloxyl acid N.D. 43.54 
M21 cp-gly-acid N.D. 43.34 
M22 cp-cyclohexane acid N.D. 43.74 
M23 cp-norbornane acid N.D. 43.26 
M24 cp-cyclopentyl acid N.D. 43.72 
N01 cp-4-ome acid N.D. 43.27 
N02 4me-acetic-acid N.D. 43.55 
N03 4me-propionic acid N.D. 43.28 
N04 4me-butyric acid N.D. 43.75 
N05 4me-isobutyric acid N.D. 43.71 
N06 4me-dimethyl acid N.D. 43.62 
N07 4me-ethyloxyl acid N.D. 43.74 
N08 4me-gly-acid N.D. 43.76 
N09 4me-cyclohexane acid N.D. 43.75 
N10 4me-norbornane acid N.D. 43.76 
N11 4me-cyclopentyl acid N.D. 43.68 
N12 4me-4-ome acid N.D. 43.32 
N13 357-acetic-acid N.D. 43.74 
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N14 357-propionic acid N.D. 43.65 
N15 357-butyric acid N.D. 43.59 
N16 357-isobutyric acid N.D. 43.41 
N17 357-dimethyl acid N.D. 43.64 
N18 357-ethyloxyl acid N.D. 43.89 
N19 357-gly-acid N.D. 43.86 
N20 357-cyclohexane acid N.D. 43.61 
N21 357-norbornane acid N.D. 43.77 
N22 357-cyclopentyl acid N.D. 43.93 
N23 357-4-ome acid N.D. 43.35 
N24 Azanitrile 1a N.D. 43.37 
O1 Azanitrile 1b N.D. 43.64 
O2 Azanitrile 1c N.D. 43.23 
O3 Azanitrile 1d N.D. 43.53 
O4 Azanitrile 1e N.D. 43.38 
O5 Azanitrile 1f N.D. 43.61 
O6 Azanitrile 1g N.D. 43.76 
O7 Azanitrile 1h N.D. 43.81 
O8 Azanitrile 1i N.D. 43.59 
O9 Azanitrile 1j N.D. 43.22 
O10 Azanitrile 1k N.D. 43.42 
O11 Azanitrile 1l N.D. 43.22 
O12 Azanitrile 1m N.D. 43.64 
O13 Azanitrile 1n N.D. 43.64 
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O14 Azanitrile 1o N.D. 43.51 
O15 Azanitrile 2 N.D. 43.58 
O16 Azanitrile 3a N.D. 43.45 
O17 Azanitrile 3b N.D. 43.88 
O18 Azanitrile 3c N.D. 43.52 
O19 Azanitrile 3d N.D. 43.54 
O20 Azanitrile 3e N.D. 43.38 
O21 Azanitrile 4 N.D. 43.25 
O22 azide library-1 N.D. 43.56 
O23 azide library-2 N.D. 43.28 
O24 azide library-3 N.D. 43.59 
P1 azide library-4 N.D. 43.88 
P2 azide library-5 N.D. 43.64 
P3 azide library-6 N.D. 43.34 
P4 azide library-7 N.D. 43.23 
P5 azide library-8 N.D. 43.33 
P6 azide library-9 N.D. 43.28 
P7 azide library-10 N.D. 43.52 
P8 azide library-11 N.D. 43.85 
P9 azide library-12 N.D. 43.74 
P10 azide library-13 N.D. 43.35 
P11 azide library-14 N.D. 43.26 
P12 azide library-15 N.D. 43.89 
P13 azide library-16 N.D. 43.28 
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P14 azide library-17 N.D. 43.64 
P15 azide library-18 N.D. 43.26 
P16 azide library-19 N.D. 43.22 
P17 azide library-20 N.D. 43.53 
P18 azide library-21 N.D. 43.31 
P19 azide library-22 N.D. 43.55 
P20 azide library-23 N.D. 43.34 
P21 azide library-24 N.D. 43.74 
P22 azide library-25 N.D. 43.27 
P23 azide library-26 N.D. 43.25 
P24 K11002 N.D. 43.46 
 
Appendix Printing pattern for Chapter 4  
 
 
ID P-3 P-2 P-1 P+1 P+2 P+3 
1 L R F V F G 
2 L R F V F E 
3 L R F V F D 
4 L R F V F N 
5 L R F V F K 
6 L R F V F A 
7 L R F V F R 
8 L R F V F L 
9 L R F V F F 
10 L R F V F Y 
11 L R F V F T 
12 L R F V F P 
13 L R F V F H 
14 L R F V F C 
15 L R F V F W 
16 L R F V F Q 
17 L R F V F M 
18 L R F V F S 
19 L R F V F V 
20 L R F V F I 
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21 L R F V G F 
22 L R F V E F 
23 L R F V D F 
24 L R F V N F 
25 L R F V K F 
26 L R F V A F 
27 L R F V R F 
28 L R F V L F 
29 L R F V F F 
30 L R F V Y F 
31 L R F V T F 
32 L R F V P F 
33 L R F V H F 
34 L R F V C F 
35 L R F V W F 
36 L R F V Q F 
37 L R F V M F 
38 L R F V S F 
39 L R F V V F 
40 L R F V I F 
41 L R F G F F 
42 L R F E F F 
43 L R F D F F 
44 L R F N F F 
45 L R F K F F 
46 L R F A F F 
47 L R F R F F 
48 L R F L F F 
49 L R F F F F 
50 L R F Y F F 
51 L R F T F F 
52 L R F P F F 
53 L R F H F F 
54 L R F C F F 
55 L R F W F F 
56 L R F Q F F 
57 L R F M F F 
58 L R F S F F 
59 L R F V F F 
60 L R F I F F 
61 L R G V F F 
62 L R E V F F 
63 L R D V F F 
64 L R N V F F 
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65 L R K V F F 
66 L R A V F F 
67 L R R V F F 
68 L R L V F F 
69 L R F V F F 
70 L R Y V F F 
71 L R T V F F 
72 L R P V F F 
73 L R H V F F 
74 L R C V F F 
75 L R W V F F 
76 L R Q V F F 
77 L R M V F F 
78 L R S V F F 
79 L R V V F F 
80 L R I V F F 
81 L G F V F F 
82 L E F V F F 
83 L D F V F F 
84 L N F V F F 
85 L K F V F F 
86 L A F V F F 
87 L R F V F F 
88 L L F V F F 
89 L F F V F F 
90 L Y F V F F 
91 L T F V F F 
92 L P F V F F 
93 L H F V F F 
94 L C F V F F 
95 L W F V F F 
96 L Q F V F F 
97 L M F V F F 
98 L S F V F F 
99 L V F V F F 
100 L I F V F F 
101 G R F V F F 
102 E R F V F F 
103 D R F V F F 
104 N R F V F F 
105 K R F V F F 
106 A R F V F F 
107 R R F V F F 
108 L R F V F F 
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109 F R F V F F 
110 Y R F V F F 
111 T R F V F F 
112 P R F V F F 
113 H R F V F F 
114 C R F V F F 
115 W R F V F F 
116 Q R F V F F 
117 M R F V F F 
118 S R F V F F 
119 V R F V F F 
120 I R F V F F 
 
 
 
 
 
 
